10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the quarterly period ended June 30, 2022

    OR

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from ____ to ____

Commission file number: 1-13648

_______________________________________________________________________________________________________________

Balchem Corporation

(Exact name of Registrant as specified in its charter)

Maryland	13-2578432
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

52 Sunrise Park Road, New Hampton, NY 10958

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (845) 326-5600

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $.06-2/3 per share	BCPC	Nasdaq Global Market

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑  No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

(Check one):	Large accelerated filer	☑	Accelerated filer	☐
	Non-accelerated filer	☐	Smaller reporting company	☐	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of July 21, 2022, the registrant had 32,120,593 shares of its Common Stock, $.06 2/3 par value, outstanding.

BALCHEM CORPORATION

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page No.
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021	3
	Condensed Consolidated Statements of Earnings for the Three and Six Months Ended June 30, 2022 and 2021	4
	Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2022 and 2021	5
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2022 and 2021	6
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.	Controls and Procedures	36
PART II	OTHER INFORMATION
Item 1A.	Risk Factors	37
Item 2C.	Issuer Purchase of Equity Securities	37
Item 6.	Exhibits	38
SIGNATURE PAGE		39

Table of Contents

Part I.    Financial Information

Item 1.    Financial Statements

BALCHEM CORPORATION

Condensed Consolidated Balance Sheets

(Dollars in thousands, except share and per share data)

Assets	June 30, 2022 (unaudited)		December 31, 2021
Current assets:
Cash and cash equivalents	$	76,183	$	103,239
Accounts receivable, net of allowance for doubtful accounts of $1,203 and $928 at June 30, 2022 and December 31, 2021 respectively	138,579		117,408
Inventories	140,840		91,058
Prepaid expenses	8,467		6,116
Derivative assets	7,276		—
Other current assets	5,796		4,411
Total current assets	377,141		322,232
Property, plant and equipment, net	252,145		237,517
Goodwill	731,772		523,949
Intangible assets with finite lives, net	218,802		94,665
Right of use assets - operating leases	10,718		6,929
Right of use assets - finance lease	2,255		2,359
Other assets	13,841		11,674
Total assets	$	1,606,674	$	1,199,325
Liabilities and Stockholders' Equity
Current liabilities:
Trade accounts payable	$	66,363	$	56,243
Accrued expenses	58,649		43,411
Accrued compensation and other benefits	14,973		19,567
Dividends payable	127		20,886
Income taxes payable	863		1,334
Operating lease liabilities - current	2,997		2,194
Finance lease liabilities - current	171		167
Total current liabilities	144,143		143,802
Revolving loan	433,569		108,569
Deferred income taxes	77,574		46,455
Operating lease liabilities - non-current	7,725		4,811
Finance lease liabilities - non-current	2,216		2,303
Derivative liabilities	—		2,658
Contingent consideration liability	24,793		—
Other long-term obligations	15,284		13,712
Total liabilities	705,304		322,310
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	—		—
Common stock, $0.0667 par value. Authorized 120,000,000 shares; 32,120,593 and 32,287,150 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	2,143		2,154
Additional paid-in capital	120,811		147,716
Retained earnings	790,840		732,138
Accumulated other comprehensive income	(12,424)		(4,993)
Total stockholders' equity	901,370		877,015
Total liabilities and stockholders' equity	$	1,606,674	$	1,199,325

See accompanying notes to condensed consolidated financial statements.

3

Table of Contents

BALCHEM CORPORATION

Condensed Consolidated Statements of Earnings

(Dollars in thousands, except per share data)

(unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net sales	$	236,693	$	202,365	$	465,560	$	388,021
Cost of sales	164,817		142,918		322,178		269,847
Gross margin	71,876		59,447		143,382		118,174
Operating expenses:
Selling expenses	15,991		14,846		32,976		29,770
Research and development expenses	2,922		2,899		6,153		5,648
General and administrative expenses	13,043		11,109		25,997		21,588
	31,956		28,854		65,126		57,006
Earnings from operations	39,920		30,593		78,256		61,168
Other expenses, net:
Interest expense, net	960		608		1,505		1,333
Other (income) expense, net	(298)		(34)		(137)		(167)
	662		574		1,368		1,166
Earnings before income tax expense	39,258		30,019		76,888		60,002
Income tax expense	9,476		7,288		18,176		13,860
Net earnings	$	29,782	$	22,731	$	58,712	$	46,142
Net earnings per common share - basic	$	0.93	$	0.71	$	1.83	$	1.43
Net earnings per common share - diluted	$	0.92	$	0.70	$	1.81	$	1.41

See accompanying notes to condensed consolidated financial statements.

4

Table of Contents

BALCHEM CORPORATION

Condensed Consolidated Statements of Comprehensive Income

(Dollars in thousands)

(unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net earnings	$	29,782	$	22,731	$	58,712	$	46,142
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(6,951)		1,524		(9,793)		(4,619)
Unrealized gain on cash flow hedge	850		351		2,423		863
Change in postretirement benefit plans	(34)		8		(61)		15
Other comprehensive income (loss)	(6,135)		1,883		(7,431)		(3,741)
Comprehensive income	$	23,647	$	24,614	$	51,281	$	42,401

See accompanying notes to condensed consolidated financial statements.

5

Table of Contents

BALCHEM CORPORATION

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the three and six months ended June 30, 2022 and 2021

(Dollars in thousands, except share and per share data)

	Total Stockholders' Equity		Retained Earnings		Accumulated Other Comprehensive (Loss) Income		Common Stock			Additional Paid-in Capital
							Shares	Amount
Balance - December 31, 2021	$	877,015	$	732,138	$	(4,993)	32,287,150	$	2,154	$	147,716
Net earnings	28,930		28,930		—		—	—		—
Other comprehensive (loss)	(1,296)		—		(1,296)		—	—		—
Repurchases of common stock	(34,599)		—		—		(245,685)	(16)		(34,583)
Dividends	(10)		(10)		—		—	—		—
Shares and options issued under stock plans	3,642		—		—		74,604	4		3,638
Balance - March 31, 2022	873,682		761,058		(6,289)		32,116,069	2,142		116,771
Net earnings	29,782		29,782		—		—	—		—
Other comprehensive (loss)	(6,135)		—		(6,135)		—	—		—
Repurchases of common stock	(600)		—		—		(4,976)	—		(600)
Shares and options issued under stock plans	4,641		—		—		9,500	1		4,640
Balance - June 30, 2022	$	901,370	$	790,840	$	(12,424)	32,120,593	$	2,143	$	120,811
Balance - December 31, 2020	$	828,233	$	656,740	$	4,173	32,372,621	$	2,160	$	165,160
Net earnings	23,411		23,411		—		—	—		—
Other comprehensive (loss)	(5,624)		—		(5,624)		—	—		—
Repurchases of common stock	(1,596)		—		—		(13,475)	(1)		(1,595)
Shares and options issued under stock plans	5,068		—		—		92,784	6		5,062
Balance - March 31, 2021	849,492		680,151		(1,451)		32,451,930	2,165		168,627
Net earnings	22,731		22,731		—		—	—		—
Other comprehensive income	1,883		—		1,883		—	—		—
Repurchases of common stock	(9,240)		—		—		(72,649)	(5)		(9,235)
Shares and options issued under stock plans	4,776		—		—		25,493	2		4,774
Balance - June 30, 2021	$	869,642	$	702,882	$	432	32,404,774	$	2,162	$	164,166

See accompanying notes to condensed consolidated financial statements.

6

Table of Contents

BALCHEM CORPORATION

Condensed Consolidated Statements of Cash Flows

(Dollars in thousands)

(unaudited)

	Six Months Ended June 30,
	2022		2021
Cash flows from operating activities:
Net earnings	$	58,712	$	46,142
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	23,861		24,463
Stock compensation expense	6,889		5,914
Deferred income taxes	1,778		54
Provision for doubtful accounts	380		(25)
Unrealized loss/(gain) on foreign currency transaction and deferred compensation	188		(401)
Asset impairment charge	23		—
Loss/(gain) on disposal of assets	203		(19)
Changes in assets and liabilities
Accounts receivable	(15,506)		(16,361)
Inventories	(33,141)		(7,949)
Prepaid expenses and other current assets	(1,733)		(2,859)
Accounts payable and accrued expenses	15,075		25,873
Income taxes	(779)		898
Other	(689)		659
Net cash provided by operating activities	55,261		76,389
Cash flows from investing activities:
Cash paid for acquisition, net of cash acquired	(295,660)		—
Capital expenditures and intangible assets acquired	(20,799)		(13,760)
Proceeds from sale of assets	197		240
Investment in affiliates	(150)		—
Net cash used in investing activities	(316,412)		(13,520)
Cash flows from financing activities:
Proceeds from revolving loan	365,000		5,000
Principal payments on revolving loan	(40,000)		(45,000)
Principal payments on acquired debt	(30,648)		—
Principal payments on finance lease	(83)		(78)
Proceeds from stock options exercised	1,328		3,886
Dividends paid	(20,704)		(18,700)
Purchase of common stock	(35,199)		(10,835)
Net cash provided by (used in) financing activities	239,694		(65,727)
Effect of exchange rate changes on cash	(5,599)		(1,811)
Decrease in cash and cash equivalents	(27,056)		(4,669)
Cash and cash equivalents beginning of period	103,239		84,571
Cash and cash equivalents end of period	$	76,183	$	79,902

See accompanying notes to condensed consolidated financial statements.

7

Table of Contents

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(All dollar amounts in thousands, except share and per share data)

NOTE 1 – CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The condensed consolidated financial statements presented herein have been prepared in accordance with the accounting policies described in the December 31, 2021 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements reflect the operations of Balchem Corporation and its subsidiaries (the "Company"). All intercompany balances and transactions have been eliminated in consolidation.

In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal, recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 (the "Exchange Act") and therefore do not include some information and notes necessary to conform to annual reporting requirements. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results expected for the full year or any interim period.

Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted the Standard Update in 2021. The adoption of the Standard update did not have a significant impact on the Company's consolidated financial statements and disclosures.

In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on the Company's consolidated financial statements and disclosures.

8

Table of Contents

NOTE 2 – SIGNIFICANT ACQUISITIONS

On June 21, 2022, Balchem and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies being hereinafter collectively referred to as “Kappa”). The Company made payments of approximately kr3,301,341 ("kr" indicates the Norwegian krone) on the acquisition date, amounting to approximately kr2,997,669 to the former shareholder and approximately kr303,672 to Kappa's lenders to pay off all Kappa bank debt. Net of cash acquired of kr63,064, total payments on the acquisition date were kr3,238,277. Considering net cash acquired of $6,365, these payments translated to approximately $326,820 paid on the acquisition date, amounting to $302,537 paid to the former shareholder and approximately $30,648 to Kappa's lenders. The acquisition was primarily financed through the 2018 Credit Agreement (see Note 8, "Revolving Loan"). In connection with this transaction, the seller has an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics are met, and therefore we recorded contingent consideration of kr245,000 (translated to $24,793) as of June 30, 2022. Kappa manufactures specialty vitamin K2, a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. Kappa's K2VITAL® branded vitamin K2 is the leading synthetic vitamin K2 and is backed by strong intellectual property and a deep clinical research portfolio. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition & Health segment.

The goodwill of $212,591 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Human Nutrition & Health business segment and is not deductible for income tax purposes.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:

Cash and cash equivalents	$	6,365
Accounts receivable	8,036
Inventories	17,701
Property, plant and equipment	9,854
Right of use assets	3,349
Customer relationships	113,545
Developed technology	18,166
Trademarks	6,055
Other assets	2,399
Accounts payable	(3,301)
Bank debt	(30,648)
Lease liabilities	(3,349)
Other liabilities	(4,373)
Deferred income taxes, net	(29,127)
Goodwill	212,591
Total consideration on acquisition date	327,263
Contingent consideration liability	(24,726)
Net gains on foreign currency exchange forward contracts	(512)
Amount paid to shareholders	302,025
Kappa bank debt paid on purchase date	30,648
Total amount paid on acquisition date	$	332,673

The estimated fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions, which are subject to change. In preparing our preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration. The purchase price and related allocation of assets acquired and liabilities assumed is preliminary pending management's final review of fair value calculations and deferred tax liabilities related to certain non-deductible assets.

9

Table of Contents

Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.

Transaction and integration costs related to the Kappa acquisition are included in selling, general, and administrative expenses and were $451 for both the three and six months ended June 30, 2022. There were no such amounts related to this acquisition for the three and six months ended June 30, 2021.

The following preliminary unaudited pro forma information has been prepared as if the acquisition had occurred on January 1, 2021.

	Three Months Ended June 30,				Six Months Ended June 30,
	Net Sales		Net Earnings		Net Sales		Net Earnings
Kappa actual results included in the Company's consolidated income statement from June 21, 2022 through June 30, 2022	$	—	$	—	$	—	$	—
2022 Supplemental pro forma combined financial information	$	247,430	$	30,172	$	489,170	$	58,648
2021 Supplemental pro forma combined financial information	$	213,032	$	26,344	$	410,649	$	50,379

Kappa's net sales and net earnings from June 21, 2022 through June 30, 2022 were not material. As such, they were not included in the Company's condensed consolidated statements of earnings for the three and six months ended June 30, 2022. 2022 supplemental pro forma net earnings for the three and six months ended June 30, 2022, excluded $643 and $722, respectively, of acquisition-related costs incurred. The pro forma information presented does not purport to be indicative of the results that actually would have been attained if the Kappa acquisition had occurred at the beginning of the periods presented, and is not intended to be a projection of future results.

NOTE 3 – STOCKHOLDERS’ EQUITY

STOCK-BASED COMPENSATION

The Company’s results for the three and six months ended June 30, 2022 and 2021 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

	Increase/(Decrease) for the				Increase/(Decrease) for the
	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cost of sales	$	277	$	444	$	676	$	744
Operating expenses	3,535		2,849		6,213		5,170
Net earnings	(2,933)		(2,547)		(5,312)		(4,569)

As allowed by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest.

The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of June 30, 2022, the plans had 534,120 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three to four years for employee restricted stock awards, three years for employee

10

Table of Contents

performance share awards, and three years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events.

Option activity for the six months ended June 30, 2022 and 2021 is summarized below:

For the six months ended June 30, 2022	Shares (000s)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2021	867	$	88.19	$	69,711
Granted	109	138.07
Exercised	(18)	72.74
Forfeited	(6)	120.36
Canceled	—	—
Outstanding as of June 30, 2022	952	$	93.99	$	34,907	6.4
Exercisable as of June 30, 2022	666	$	81.11	$	32,409	5.4

For the six months ended June 30, 2021	Shares (000s)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2020	858	$	80.58	$	29,735
Granted	129	119.12
Exercised	(58)	65.95
Forfeited	(2)	101.38
Canceled	(1)	74.57
Outstanding as of June 30, 2021	926	$	86.85	$	41,107	6.8
Exercisable as of June 30, 2021	580	$	73.72	$	33,398	5.6

ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.5% and 0.5%; expected volatilities of 31% and 33%; risk-free interest rates of 2.0% and 0.5%; and expected lives of 4.9 years and 4.9 years, in each case for the six months ended June 30, 2022 and 2021, respectively.

The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury Zero coupon issues with a remaining term equal to the expected life.

11

Table of Contents

Other information pertaining to option activity during the three and six months ended June 30, 2022 and 2021 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Weighted-average fair value of options granted	$	—	$	34.42	$	40.26	$	33.11
Total intrinsic value of stock options exercised ($000s)	$	495	$	1,814	$	1,149	$	3,731

Non-vested restricted stock activity for the six months ended June 30, 2022 and 2021 is summarized below:

	Six Months Ended June 30,
	2022			2021
	Shares (000s)	Weighted Average Grant Date Fair Value		Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31	166	$	99.70	159	$	90.71
Granted	34	137.74		37	119.30
Vested	(77)	80.84		(13)	87.33
Forfeited	(3)	116.73		(2)	85.60
Non-vested balance as of June 30	120	$	122.03	181	$	96.89

Non-vested performance share activity for the six months ended June 30, 2022 and 2021 is summarized below:

	Six Months Ended June 30,
	2022			2021
	Shares (000s)	Weighted Average Grant Date Fair Value		Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31	69	$	110.72	71	$	91.99
Granted	39	114.22		36	108.74
Vested	(35)	53.17		(24)	70.64
Forfeited	(3)	84.09		(11)	74.57
Non-vested balance as of June 30	70	$	127.69	72	$	110.22

The performance share (“PS”) awards provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and relative total shareholder return (TSR) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 1.8% and 0.2%; dividend yields of 0.5% and 0.6%; volatilities of 32% and 33%; and initial TSR’s of -15.7% and 11.7%, in each case for the six months ended June 30, 2022 and 2021, respectively. Expense is estimated based on the number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved.  The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.

As of June 30, 2022 and 2021, there were $19,988 and $19,796, respectively, of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the plans. As of June 30, 2022, the unrecognized

12

Table of Contents

compensation cost is expected to be recognized over a weighted-average period of approximately 1.7 years. The Company estimates that share-based compensation expense for the year ended December 31, 2022 will be approximately $13,000.

REPURCHASE OF COMMON STOCK

The Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,068,905 shares have been purchased. The Company’s prior presentation of reflecting treasury stock separately within stockholders’ equity has been adjusted to conform to the presentation prescribed by the State of Maryland, where the Company is incorporated. In connection therewith, adjustments to balances previously reflected as treasury stock of $8,472, $2,210, and $7,873 as of June 30, 2021, March 31, 2021, and December 31, 2020, respectively, were made to the condensed consolidated statements of changes in stockholders’ equity and prior references to “Treasury shares purchased” were updated to “Repurchases of common stock”, accordingly. There was no impact to total stockholders’ equity in any of the years presented as a result of these updates. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. During the six months ended June 30, 2022 and 2021, the Company purchased 250,661 and 86,124 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $140.42 and $125.81, respectively.

NOTE 4 – INVENTORIES

Inventories at June 30, 2022 and December 31, 2021 consisted of the following:

	June 30, 2022		December 31, 2021
Raw materials	$	43,342	$	28,639
Work in progress	20,249		10,563
Finished goods	77,249		51,856
Total inventories	$	140,840	$	91,058

NOTE 5 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at June 30, 2022 and December 31, 2021 are summarized as follows:

	June 30, 2022		December 31, 2021
Land	$	11,273	$	11,692
Building	91,140		89,602
Equipment	263,929		253,995
Construction in progress	65,906		52,930
	432,248		408,219
Less: accumulated depreciation	180,103		170,702
Property, plant and equipment, net	$	252,145	$	237,517

NOTE 6 – INTANGIBLE ASSETS

The Company had goodwill in the amount of $731,772 and $523,949 as of June 30, 2022 and December 31, 2021, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The increase in goodwill is the result of the acquisition of Kappa, partially offset by the change due to foreign exchange translation adjustments. Refer to Note 2, "Significant Acquisitions", for more information.

13

Table of Contents

Identifiable intangible assets with finite lives at June 30, 2022 and December 31, 2021 are summarized as follows:

	Amortization Period (in years)	Gross Carrying Amount at 6/30/2022		Accumulated Amortization at 6/30/2022		Gross Carrying Amount at 12/31/2021		Accumulated Amortization at 12/31/2021
Customer relationships & lists	10-20	$	350,523	$	180,638	$	240,059	$	173,489
Trademarks & trade names	2-17	48,724		30,968		43,116		28,985
Developed technology	5-12	38,252		14,993		20,234		14,607
Other	2-18	24,687		16,785		23,921		15,584
		$	462,186	$	243,384	$	327,330	$	232,665

Amortization of identifiable intangible assets was approximately $5,850 and $11,761 for the three and six months ended June 30, 2022, respectively, and $6,229 and $12,713 for the three and six months ended June 30, 2021, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, estimated amortization expense is $14,485 for the remainder of 2022, $27,923 for 2023, $19,659 for 2024, $16,117 for 2025, $15,710 for 2026 and $14,949 for 2027. At June 30, 2022 and December 31, 2021, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in “Intangible assets with finite lives, net” in the Company’s condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the six months ended June 30, 2022 and 2021.

NOTE 7 – EQUITY-METHOD INVESTMENT

In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company receives up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance.  The Company recognized a loss of $140 and $280 for the three and six months ended June 30, 2022, respectively, and $130 and $274 for the three and six months ended June 30, 2021, respectively, relating to its portion of the joint venture's expenses in other expense. The Company made capital contributions to the investment totaling $75 and $133 for the three and six months ended June 30, 2022, respectively, and received a net return of capital totaling $28 and $15 for the three and six months ended June 30, 2021, respectively. The carrying value of the joint venture at June 30, 2022 and December 31, 2021 was $4,352 and $4,499, respectively, and is recorded in "Other assets."

NOTE 8 – REVOLVING LOAN

On June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "2018 Credit Agreement"), which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000.  The 2018 Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”).  The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion.  The initial proceeds from the 2018 Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. During the second quarter of 2022, the Company borrowed an additional $345,000 to fund the Kappa acquisition (see Note 2, "Significant Acquisitions"). As of June 30, 2022 and December 31, 2021, the total balance outstanding on the 2018 Credit Agreement amounted to $433,569 and $108,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. On July 27, 2022, the Company entered into an Amended and Restated Credit Agreement with lenders in the form of a senior secured revolving credit facility, due July 27, 2027. The Amended and Restated Credit Agreement allows for up to $550,000 of borrowing. The Company used initial proceeds from the Amended and Restated Credit Agreement to repay the outstanding balance of $433,569 on the previous revolving credit facility, due June 2023. In connection with the entering into the Amended and Restated Credit Agreement, the Company also modified its existing interest rate swap under the relief provided for in ASC 848, "Reference Rate Reform" (see Note 20 "Derivative Instruments and Hedging Activities").

14

Table of Contents

Amounts outstanding under the 2018 Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the 2018 Credit Agreement plus an applicable rate.  The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the 2018 Credit Agreement, and the interest rate was 2.538% at June 30, 2022. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the 2018 Credit Agreement and ranges from 0.15% to 0.275% (0.15% at June 30, 2022).  The unused portion of the revolving loan amounted to $66,431 at June 30, 2022.  The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.

Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the 2018 Credit Agreement, which is not materially different than the effective interest method.  Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $280 and $421 at June 30, 2022 and December 31, 2021, respectively, and are included in other assets on the condensed consolidated balance sheets. Amortization expense pertaining to these costs totaled $70 and $141 for the three and six months ended June 30, 2022 and 2021, respectively, and are included in "Interest expense" in the accompanying condensed consolidated statements of earnings.

The 2018 Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio.  At June 30, 2022, the Company was in compliance with these covenants.  Indebtedness under the Company’s loan agreements is secured by assets of the Company.

NOTE 9– NET EARNINGS PER SHARE

The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net Earnings - Basic and Diluted	$	29,782	$	22,731	$	58,712	$	46,142
Shares (000s)
Weighted Average Common Shares - Basic	31,999		32,232		32,020		32,243
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares	315		419		375		410
Weighted Average Common Shares - Diluted	32,314		32,651		32,395		32,653
Net Earnings Per Share - Basic	$	0.93	$	0.71	$	1.83	$	1.43
Net Earnings Per Share - Diluted	$	0.92	$	0.70	$	1.81	$	1.41

The number of anti-dilutive shares were 294,568 and 237,453 for the three and six months ended June 30, 2022, respectively, and 153,868 and 304,324 for the three and six months ended June 30, 2021, respectively. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.

NOTE 10 – INCOME TAXES

The Company’s effective tax rate for the three months ended June 30, 2022 and 2021, was 24.1% and 24.3%, respectively, and 23.6% and 23.1% for the six months ended June 30, 2022 and 2021. The decrease in the effective tax rate for the three months ended June 30, 2022 compared to the three months ended June 30, 2021 was primarily due to the prior year being negatively impacted by clarifying regulations related to tax reform, which was offset by lower tax benefits from stock-based compensation in the current quarter. The increase in the effective tax rate for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 was primarily due to lower tax benefits from stock-based compensation and a reduction in certain tax credits.

Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the Securities and Exchange Commission ("SEC"), and/or the Financial Accounting Standards Board ("FASB") regarding this act.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are

15

Table of Contents

measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences.

The Company accounts for uncertainty in income taxes utilizing ASC 740-10, "Income Taxes". ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. It prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken. This interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosures. The application of ASC 740-10 requires judgment related to the uncertainty in income taxes and could impact our effective tax rate.

The Company files income tax returns in the U.S. and in various states and foreign countries. As of June 30, 2022, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2017. As of June 30, 2022 and December 31, 2021, the Company had approximately $5,902 and $5,881, respectively, of unrecognized tax benefits, which are included in "Other long-term obligations" on the Company’s condensed consolidated balance sheets. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of "Income tax expense" in the condensed consolidated statements of earnings. The total amounts of accrued interest and penalties related to uncertain tax positions at June 30, 2022 and December 31, 2021 were approximately $2,214 and $2,106, respectively, and are included in "Other long-term obligations."

NOTE 11 – SEGMENT INFORMATION

Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated."

Human Nutrition & Health

The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Through the Kappa acquisition, this segment recently began manufacturing specialty vitamin K2, which is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance.

Animal Nutrition & Health

The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine

16

Table of Contents

industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity.

Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace.

Specialty Products

Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. The Company’s 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.

The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment.

The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life.  First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.

The segment information is summarized as follows:

Business Segment Assets	June 30, 2022		December 31, 2021
Human Nutrition & Health	$	1,146,749	$	727,131
Animal Nutrition & Health	171,605		158,971
Specialty Products	179,573		184,628
Other and Unallocated (1)	108,747		128,595
Total	$	1,606,674	$	1,199,325

17

Table of Contents

Business Segment Net Sales	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	131,628	$	111,471	$	254,073	$	215,987
Animal Nutrition & Health	62,600		54,481		131,942		105,629
Specialty Products	36,647		34,022		69,981		62,030
Other and Unallocated (2)	5,818		2,391		9,564		4,375
Total	$	236,693	$	202,365	$	465,560	$	388,021

Business Segment Earnings Before Income Taxes	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	23,705	$	19,021	$	44,008	$	38,711
Animal Nutrition & Health	7,586		3,561		18,907		8,617
Specialty Products	9,919		9,729		17,680		16,918
Other and Unallocated (2)	(1,290)		(1,718)		(2,339)		(3,078)
Interest and other expense	(662)		(574)		(1,368)		(1,166)
Total	$	39,258	$	30,019	$	76,888	$	60,002

Depreciation/Amortization	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	7,392	$	7,441	$	14,747	$	15,014
Animal Nutrition & Health	1,668		1,816		3,329		3,580
Specialty Products	1,899		2,085		3,831		4,354
Other and Unallocated (2)	974		757		1,954		1,515
Total	$	11,933	$	12,099	$	23,861	$	24,463

Capital Expenditures	Six Months Ended June 30,
	2022		2021
Human Nutrition & Health	$	11,006	$	8,883
Animal Nutrition & Health	6,559		2,729
Specialty Products	2,206		1,448
Other and Unallocated (2)	338		66
Total	$	20,109	$	13,126

(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.

(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $872 and $1,176 for the three and six months ended June 30, 2022, respectively, and $466 and $700 for the three and six months ended June 30, 2021, respectively, and (ii) Unallocated amortization expense of $811 and $1,620 for the three and six months ended June 30, 2022, respectively, and $674 and $1,349 for the three and six months ended June 30, 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that were included in interest expense in the Company's condensed consolidated statements of earnings.

18

Table of Contents

NOTE 12 – REVENUE

Revenue Recognition

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to realize in exchange for those goods.

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product Sales	$	225,260	$	193,122	$	443,313	$	369,110
Co-manufacturing	9,819		6,878		18,126		14,156
Consignment	989		1,380		2,580		2,431
Product Sales Revenue	236,068		201,380		464,019		385,697
Royalty Revenue	625		985		1,541		2,324
Total Revenue	$	236,693	$	202,365	$	465,560	$	388,021

The following table presents revenues disaggregated by geography, based on the shipping addresses of customers:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	169,076	$	147,188	$	343,567	$	285,039
Foreign Countries	67,617		55,177		121,993		102,982
Total Revenue	$	236,693	$	202,365	$	465,560	$	388,021

Product Sales Revenues

The Company’s primary operation is the manufacturing and sale of health and nutrition ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of three sub-streams: product sales, co-manufacturing, and consignment.

Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials.  The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer.  Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided.

Royalty Revenues

Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.

Contract Liabilities

The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.

The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.

Practical Expedients and Exemptions

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

19

Table of Contents

The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.

NOTE 13 – SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid during the six months ended June 30, 2022 and 2021 for income taxes and interest is as follows:

	Six Months Ended June 30,
	2022		2021
Income taxes	$	15,562	$	12,493
Interest	$	1,960	$	2,452

NOTE 14 – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The changes in accumulated other comprehensive (loss)/income were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net foreign currency translation adjustment	$	(6,951)	$	1,524	$	(9,793)	$	(4,619)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized gain on cash flow hedge	1,122		456		3,206		1,133
Tax	(272)		(105)		(783)		(270)
Net of tax	850		351		2,423		863
Net change in postretirement benefit plan (see Note 15 for further information)
Amortization of prior service cost	2		19		4		37
Amortization of gain	—		(7)		—		(12)
Gain arising during the period and prior service credit	(9)		—		(41)		(4)
Total before tax	(7)		12		(37)		21
Tax	(27)		(4)		(24)		(6)
Net of tax and adjustment	(34)		8		(61)		15
Total other comprehensive (loss)/income	$	(6,135)	$	1,883	$	(7,431)	$	(3,741)

Included in "Net foreign currency translation adjustment" were gains of $3,963 and $5,086, related to a net investment hedge, which were net of taxes of $1,309 and $1,642 for the three and six months ended June 30, 2022, respectively. Included in "Net foreign currency translation adjustment" was a loss of $1,024 and a gain of $2,173, related to a net investment hedge, which were net of taxes of $336 and $690 for the three and six months ended June 30, 2021, respectively. See Note 20, "Derivative Instruments and Hedging Activities."

20

Table of Contents

Accumulated other comprehensive (loss)/income at June 30, 2022 and December 31, 2021 consisted of the following:

	Foreign currency translation adjustment		Cash flow hedge		Postretirement benefit plan		Total
Balance December 31, 2021	$	(3,602)	$	(1,631)	$	240	$	(4,993)
Other comprehensive (loss)/income	(9,793)		2,423		(61)		(7,431)
Balance June 30, 2022	$	(13,395)	$	792	$	179	$	(12,424)

NOTE 15 – EMPLOYEE BENEFIT PLANS

Defined Contribution Plans

The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1st, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. On June 21, 2022, the Company completed the acquisition of Kappa, which sponsors one defined contribution plan for its employees.

Postretirement Medical Plans

The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona facility and a plan for those named as executive officers in the Company’s proxy statement.

Net periodic benefit costs for such retirement medical plans were as follows:

	Six Months Ended June 30,
	2022		2021
Service cost	$	39	$	43
Interest cost	13		12
Amortization of prior service cost	4		37
Amortization of gain	—		(12)
Net periodic benefit cost	$	56	$	80

The amounts recorded for these obligations on the Company’s condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021 are $1,221 and $1,293, respectively, and are included in "Other long-term obligations." These plans are unfunded and approved claims are paid from Company funds. Historical cash payments made under such plans have typically been less than $200 per year.

Defined Benefit Pension Plans

On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amounts recorded for these obligations on the Company's condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021 were $641 and $684, respectively, and were included in "Other long-term obligations."

21

Table of Contents

Net periodic benefit costs for such benefit pensions plans were as follows:

	Six Months Ended June 30,
	2022		2021
Service cost with interest to end of year	$	29	$	35
Interest cost	12		7
Expected return on plan assets	(25)		(18)
Amortization of gain	—		2
Total net periodic benefit cost	$	16	$	26

Deferred Compensation Plan

On June 1, 2018, the Company established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees.  Assets of the plan are held in a rabbi trust, and are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company.  The deferred compensation liability was $8,252 as of June 30, 2022, of which $8,220 was included in "Other long-term obligations" and $32 was included in "Accrued compensation and other benefits" on the Company's condensed consolidated balance sheets. The deferred compensation liability was $6,270 as of December 31, 2021, of which $6,251 was included in "Other long-term obligations" and $19 was included in "Accrued compensation and other benefits" on the Company’s condensed consolidated balance sheets. The related rabbi trust assets were $8,255 and $6,267 as of June 30, 2022 and December 31, 2021, respectively, and were included in "Other non-current assets" on the Company's condensed consolidated balance sheets.

NOTE 16 – COMMITMENTS AND CONTINGENCIES

Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at June 30, 2022 are as follows:

Year
July 1, 2022 to December 31, 2022	$	1,896
2023	3,551
2024	3,754
2025	2,824
2026	2,451
2027	2,093
Thereafter	6,225
Total minimum lease payments	$	22,794

The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for certain potential liabilities associated with the Superfund site. In February 2022, BCP Ingredients, Inc. ("BCP"), the Company subsidiary that operates the site, along with the prior owner of the site received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study ("RI/FS") at the site with regard to the presence of certain contaminants at the site, focusing primarily on the presence of 1,4 dioxane and chlorobenzene. BCP and the site's prior owner are currently negotiating with the EPA and the State of Missouri with respect to a proposed Administrative Settlement Agreement and Order on Consent that defines the scope and performance of the focused RI/FS.

From time to time, the Company is a party to various litigation, claims and assessments.  Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

22

Table of Contents

NOTE 17 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at June 30, 2022 and December 31, 2021 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio.  The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at June 30, 2022 and December 31, 2021 includes $927 and $933 in money market funds, respectively.

Non-current assets at June 30, 2022 and December 31, 2021 includes $8,255 and $6,267, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”

The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in "Derivative assets" or "Derivative liabilities" in the Company's condensed consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The derivative assets related to the cross-currency swap and the interest rate swap were $6,228 and $1,048 at June 30, 2022, respectively. The derivative liability related to the cross-currency swap and the interest rate swap was $500 and $2,158 at December 31, 2021, respectively.

NOTE 18 – RELATED PARTY TRANSACTIONS

The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the condensed consolidated statements of earnings.

Payments for the services the Company provided amounted to $1,022 and $1,997 for the three and six months ended June 30, 2022, respectively, and $920 and $1,747 for the three and six months ended June 30, 2021, respectively. The raw materials purchased and subsequently sold amounted to $10,910 and $20,221 for the three and six months ended June 30, 2022, respectively, and $6,580 and $12,042 for the three and six months ended June 30, 2021, respectively. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $8,233 and $14,722 for the three and six months ended June 30, 2022, respectively, and $5,210 and $9,601 for the three and six months ended June 30, 2021, respectively. At June 30, 2022 and December 31, 2021, the Company had receivables of $8,224 and $10,504, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold. The Company also had payables of $5,829 and $7,552, respectively, recorded in accounts payable for finished goods received from St. Gabriel CC Company, LLC. In addition, the Company had receivables in the amount of $164 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of December 31, 2021. There were no such receivables as of June 30, 2022. The Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of both June 30, 2022 and December 31, 2021.

NOTE 19 – LEASES

The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from June 30, 2022. In addition, the Company has historically not been exercising purchase options under the equipment leases as it

23

Table of Contents

does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

On June 22, 2022, the Company signed a ten-year real estate sublease for approximately 40,000 square feet of office space, which will serve as the Company's corporate headquarters and a laboratory facility. The sublease will not commence until the sublandlord substantially completes its work per the sublease agreement, which will most likely occur in the third quarter of 2022. This new sublease will replace the current lease for the Company's corporate headquarters, however the Company anticipates that it will continue to lease the laboratory space in the previous corporate headquarters. The Company will recognize a right of use asset and a lease liability at the commencement date based on ASC 842, Lease Accounting. As of June 30, 2022 the Company did not record a right of use asset or lease liability on the balance sheet in connection with this lease.

The Company has not identified any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the condensed consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2022: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%.

In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At June 30, 2022 and December 31, 2021, the Company had finance lease liabilities of $2,387 and $2,470, respectively, which were recorded under "Lease liabilities" (current and non-current) on the condensed consolidated balance sheets.

Right of use assets and lease liabilities at June 30, 2022 and December 31, 2021 are summarized as follows:

Right of use assets	June 30, 2022		December 31, 2021
Operating leases	$	10,718	$	6,929
Finance leases	2,255		2,359
Total	$	12,973	$	9,288

Lease liabilities - current	June 30, 2022		December 31, 2021
Operating leases	$	2,997	$	2,194
Finance leases	171		167
Total	$	3,168	$	2,361

Lease liabilities - non-current	June 30, 2022		December 31, 2021
Operating leases	$	7,725	$	4,811
Finance leases	2,216		2,303
Total	$	9,941	$	7,114

24

Table of Contents

For the three and six months ended June 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Lease Cost
Operating lease cost	$	811		$	770		$	1,592		$	1,486
Finance Lease cost
Amortization of ROU asset	52			53			104			105
Interest on lease liabilities	30			33			61			66
Total finance lease	82			86			165			171
Total lease cost	$	893		$	856		$	1,757		$	1,657
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	807		$	749		$	1,608		$	1,488
Operating cash flows from finance leases	30			33			61			66
Financing cash flows from finance leases	42			39			83			78
	$	879		$	821		$	1,752		$	1,632
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$	4,615		$	1,376		$	5,277		$	2,412
Weighted-average remaining lease term - operating leases	4.10 years			4.43 years			4.10 years			4.43 years
Weighted-average remaining lease term - finance leases	10.91 years			11.75 years			10.91 years			11.75 years
Weighted-average discount rate - operating leases	3.2		%	3.9		%	3.2		%	3.9		%
Weighted-average discount rate - finance leases	5.1		%	5.1		%	5.1		%	5.1		%

Rent expense charged to operations under operating lease agreements for the three and six months ended June 30, 2022 aggregated to approximately $811 and $1,592, respectively, and $770 and $1,486 for the three and six months ended June 30, 2021, respectively.

NOTE 20 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap (net investment hedge) with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk.

On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the 2018 Credit Agreement. The net interest expense related to the interest rate swap contract was $364 and $877 for the three and six months ended June 30, 2022, and $534 and $1,055 for the three and six months ended June 30, 2021, respectively, and was recorded in the condensed consolidated statements of earnings under "Interest expense, net." In addition, in connection with the Company's entering into the Amended

25

Table of Contents

and Restated Credit Agreement on July 27, 2022 (see Note 8 "Revolving Loan"), the Company also modified its existing interest rate swap under the relief provided for in ASC 848, "Reference Rate Reform".

On May 28, 2019, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $563 and $1,113 for the three and six months ended June 30, 2022, and $563 and $1,119 for the three and six months ended June 30, 2021, respectively, which were recorded in the condensed consolidated statements of earnings under "Interest expense, net."

The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net "Derivative asset" or "Derivative liability" on the condensed consolidated balance sheets.

As of June 30, 2022 and December 31, 2021, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets:

Derivative assets (liabilities)	June 30, 2022		December 31, 2021
Interest rate swap	$	1,048	$	(2,158)
Cross-currency swap	6,228		(500)
Derivative assets (liabilities)	$	7,276	$	(2,658)

On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.

In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.

If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting.

As of June 30, 2022, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income.

26

Table of Contents

Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and six months ended June 30, 2022 and 2021:

	Location within Statements of Comprehensive Income	Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021		2022		2021
Cash flow hedge (interest rate swap), net of tax	Unrealized gain/(loss) on cash flow hedge, net	$	850	$	351	$	2,423	$	863
Net investment hedge (cross-currency swap), net of tax	Net foreign currency translation adjustment	3,963		(1,024)		5,086		2,173
Total		$	4,813	$	(673)	$	7,509	$	3,036

On June 21, 2022, the Company completed the acquisition of Kappa (as defined in Note 2 "Significant Acquisitions"). In the process of acquiring Kappa, the Company entered into four short-term foreign currency exchange forward contracts with JP Morgan Chase, N.A to manage fluctuations in foreign currency exchange rates related to the acquisition. The Company did not designate these contracts as hedged transactions under the applicable sections of ASC Topic 815, "Derivatives and Hedging". For the six months ended June 30, 2022, the net gains on these forward contracts of $512 were recorded in other income or loss in the condensed consolidated statements of earnings. As of June 30, 2022, the Company did not maintain any open foreign currency exchange forward contracts as all four contracts expired before June 30, 2022.

The following table summarizes the key terms of the four forward exchange contracts:.

Date entered into	Date expired on	Balchem to sell		Balchem to buy
June 15, 2022	June 21, 2022	USD	294,555	NOK	2,924,553
June 15, 2022	June 17, 2022	USD	6,436	EUR	6,180
June 15, 2022	June 21, 2022	USD	16,640	EUR	15,972
June 15, 2022	June 21, 2022	EUR	15,972	NOK	165,210

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations (All amounts in thousands, except share and per share data)

This report contains forward-looking statements, within the meaning of Section 21E of the Exchange Act, which reflect our expectation or belief concerning future events that involve risks and uncertainties. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2021 and other factors that may be identified elsewhere in this report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements.

Overview

We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, as more fully described in Note 11 of the condensed consolidated financial statements. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

Balchem is committed to solving today's challenges to shape a healthier tomorrow by operating responsibly and providing innovative solutions for the health and nutritional needs of the world. Sustainability is at the heart of our company's vision to make the world a healthier place, and we proudly support the Ten Principles of the United Nations Global Compact on human rights, labor, environment and anti-corruption. In January 2022, Balchem was named one of America’s Most Responsible Companies by Newsweek magazine for the second consecutive year. This list, compiled by Newsweek in partnership with Statista Inc., recognizes the most responsible companies in the U.S. across a variety of industries, and is based on publicly available environmental, social and governance (ESG) data. Our Sustainability Framework focuses on the most critical ESG topics relevant to our business and stakeholders. We are very proud of our ESG accomplishments to date and are pleased with the recognition by

27

Table of Contents

Newsweek. Balchem will continue to foster these fundamental principles broadly along our entire value chain, develop new ideas and technologies that help us work smarter, and help build a world that is a better place to live.

As of June 30, 2022, we employed approximately 1,359 full time employees worldwide. Although we are facing challenging labor markets, we believe that we have been successful in attracting skilled and experienced personnel in a competitive environment and that our human capital resources are adequate to perform all business functions. In addition, we continue to enhance technology in order to optimize productivity and performance.

Acquisition of Kappa

On June 21, 2022, we completed the acquisition of Kappa (as defined in Note 2 "Significant Acquisitions"), a leading science-based manufacturer of specialty Vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. Details related to the Kappa acquisition are disclosed in Note 2, "Significant Acquisitions". The acquisition strengthens our scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for Balchem's portfolios within the Human Nutrition & Health segment.

COVID-19 Response

The COVID-19 response effort has been a significant focus for us since early 2020. Our focus has been on employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate.

As a result of our broad based risk mitigation efforts against the direct impacts of the Covid-19 pandemic, our manufacturing sites have been operating at near normal conditions, our research and development teams have continued to innovate in our laboratories, and all of our other employees have been effectively carrying on their responsibilities and functions remotely or in a reduced density hybrid setting.

We are increasingly focused on managing the extraordinary supply chain disruptions that are challenging the markets we operate within that are, at least in part, related to the pandemic and/or the global recovery from the pandemic. We are experiencing severe input cost inflation, raw material shortages, logistics disruptions, and labor availability issues. These indirect pandemic related challenges accelerated as 2021 progressed, continued into the first and second quarters of 2022, and are likely to continue for some time.

Segment Results

We sell products for all three segments through our own sales force, independent distributors, and sales agents.

The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three and six months ended June 30, 2022 and 2021:

Business Segment Net Sales	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	131,628	$	111,471	$	254,073	$	215,987
Animal Nutrition & Health	62,600		54,481		131,942		105,629
Specialty Products	36,647		34,022		69,981		62,030
Other and Unallocated (1)	5,818		2,391		9,564		4,375
Total	$	236,693	$	202,365	$	465,560	$	388,021

28

Table of Contents

Business Segment Earnings From Operations	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	23,705	$	19,021	$	44,008	$	38,711
Animal Nutrition & Health	7,586		3,561		18,907		8,617
Specialty Products	9,919		9,729		17,680		16,918
Other and Unallocated (1)	(1,290)		(1,718)		(2,339)		(3,078)
Total	$	39,920	$	30,593	$	78,256	$	61,168

(1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $872 and $1,176 for the three and six months ended June 30, 2022, respectively, and $466 and $700 for the three and six months ended June 30, 2021, respectively, and (ii) Unallocated amortization expense of $741 and $1,479 for the three and six months ended June 30, 2022, respectively, and $604 and $1,208 for the three and six months ended June 30, 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.

RESULTS OF OPERATIONS

(All amounts in thousands, except share and per share data)

Three months ended June 30, 2022 compared to three months ended June 30, 2021.

Net Earnings

	Three Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Net sales	$	236,693	$	202,365	$	34,328	17.0	%
Gross margin	71,876		59,447		12,429		20.9	%
Operating expenses	31,956		28,854		3,102		10.8	%
Earnings from operations	39,920		30,593		9,327		30.5	%
Other (income) expense, net	662		574		88		15.3	%
Income tax expense	9,476		7,288		2,188		30.0	%
Net earnings	$	29,782	$	22,731	$	7,051	31.0	%

Net Sales

	Three Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Human Nutrition & Health	$	131,628	$	111,471	$	20,157	18.1	%
Animal Nutrition & Health	62,600		54,481		8,119		14.9	%
Specialty Products	36,647		34,022		2,625		7.7	%
Other	5,818		2,391		3,427		143.3	%
Total	$	236,693	$	202,365	$	34,328	17.0	%

•The increase in net sales within the Human Nutrition & Health segment for the second quarter of 2022 as compared to the second quarter of 2021 was driven both by sales growth within food and beverage markets as well as higher sales within the minerals and nutrients business. Total sales for this segment grew 18.1%, with average selling prices contributing 16.2%, volume and mix contributing 2.2%, and the change in foreign currency exchange rates contributing -0.3%.

•The increase in net sales within the Animal Nutrition & Health segment for the second quarter of 2022 compared to the second quarter of 2021 was the result of higher sales in monogastric and companion animal markets, partially offset by lower

29

Table of Contents

sales in ruminant animal markets and an unfavorable impact related to changes in foreign currency exchange rates. Total sales for this segment grew 14.9%, with average selling prices contributing 28.1%, the change in foreign currency exchange rates contributing -3.4%, and volume and mix contributing -9.9%.

•The increase in Specialty Products segment sales for the second quarter of 2022 compared to 2021 was due to higher sales of products in the medical device sterilization market, partially offset by lower plant nutrition sales, and an unfavorable impact related to changes in foreign currency exchange rates. Total sales for this segment grew 7.7% with average selling prices contributing 17.4%, volume and mix contributing -7.0%, and the change in foreign currency exchange rates contributing -2.7%.

•Sales relating to Other increased from the prior year due to higher demand.

•Sales may fluctuate in future periods based on macroeconomic conditions, competitive dynamics, changes in customer preferences, and our ability to successfully introduce new products to the market.

Gross Margin

	Three Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Gross margin	$	71,876		$	59,447		$	12,429	20.9	%
% of net sales	30.4		%	29.4		%

Gross margin dollars increased in the second quarter of 2022 compared to the second quarter of 2021 due to the aforementioned higher sales of $34,328, partially offset by an increase in cost of goods sold of $21,899. The 15.3% increase in cost of goods sold was driven mainly by the higher sales as well as the significant inflation of manufacturing input costs, primarily related to raw materials, partially offset by the timing of costs associated with the recovery from a flash flood event at our Verona manufacturing facility in the prior year.

Operating Expenses

	Three Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Operating expenses	$	31,956		$	28,854		$	3,102	10.8	%
% of net sales	13.5		%	14.3		%

The increase in operating expenses was primarily due to certain higher compensation-related costs of $1,544 and higher advertising and marketing expenses of $555.

Earnings from Operations

	Three Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Human Nutrition & Health	$	23,705		$	19,021		$	4,684	24.6	%
Animal Nutrition & Health	7,586			3,561			4,025		113.0	%
Specialty Products	9,919			9,729			190		2.0	%
Other and unallocated	(1,290)			(1,718)			428		24.9	%
Earnings from operations	$	39,920		$	30,593		$	9,327	30.5	%
% of net sales (operating margin)	16.9		%	15.1		%

•Earnings from operations for the Human Nutrition & Health segment increased primarily due to the aforementioned higher sales. Gross margin as a percentage of sales remained relatively flat as a significant increase in certain manufacturing input

30

Table of Contents

costs, largely related to raw materials, was offset by the timing of costs associated with the recovery of a flash flood event at our Verona facility in the prior year. Additionally, total operating expenses for this segment increased by $1,453, primarily due to higher compensation-related costs of $785.

•Animal Nutrition & Health segment earnings from operations increased primarily due to the aforementioned higher sales and a 500 basis point increase in gross margin as a percentage of sales, due to the timing of costs associated with the recovery of a flash flood event at our Verona facility in the prior year, partially offset by a significant increase in certain manufacturing input costs, largely related to raw materials. Additionally, operating expenses for this segment increased by $550, primarily due to higher advertising and marketing expenses of $317 and higher compensation-related costs of $250.

•The increase in earnings from operations for the Specialty Products segment was primarily due to the aforementioned higher sales, partially offset by a 160 basis point decrease in gross margin as a percentage of sales, due to a significant increase in certain manufacturing input costs, largely related to raw materials. Additionally, total operating expenses for this segment increased by $502, primarily related to higher compensation-related costs of $458.

•The increase in Other and unallocated was primarily driven by the aforementioned higher sales, partially offset by an increase in transaction costs, primarily related to the Kappa acquisition.

Other Expenses (Income)

	Three Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Interest expense	$	960	$	608	$	352	57.9	%
Other, net	(298)		(34)		(264)		776.5	%
	$	662	$	574	$	88	15.3	%

Interest expense for the three months ended June 30, 2022 and 2021 was primarily related to outstanding borrowings under the 2018 Credit Agreement.  

Income Tax Expense

	Three Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Income tax expense	$	9,476		$	7,288		$	2,188	30.0	%
Effective tax rate	24.1		%	24.3		%

The decrease in the effective tax rate was primarily due to the prior year being negatively impacted by clarifying regulations related to tax reform, which was offset by lower tax benefits from stock-based compensation in the current quarter.

31

Table of Contents

Six months ended June 30, 2022 compared to six months ended June 30, 2021.

Net Earnings

	Six Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Net sales	$	465,560	$	388,021	$	77,539	20.0	%
Gross margin	143,382		118,174		25,208		21.3	%
Operating expenses	65,126		57,006		8,120		14.2	%
Earnings from operations	78,256		61,168		17,088		27.9	%
Other expense, net	1,368		1,166		202		17.3	%
Income tax expense	18,176		13,860		4,316		31.1	%
Net earnings	$	58,712	$	46,142	$	12,570	27.2	%

Net Sales

	Six Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Human Nutrition & Health	$	254,073	$	215,987	$	38,086	17.6	%
Animal Nutrition & Health	131,942		105,629		26,313		24.9	%
Specialty Products	69,981		62,030		7,951		12.8	%
Other	9,564		4,375		5,189		118.6	%
Total	$	465,560	$	388,021	$	77,539	20.0	%

•The increase in net sales within the Human Nutrition & Health segment for the six months ended June 30, 2022 as compared to 2021 was primarily attributed to sales growth within food and beverage markets. Total sales for this segment grew 17.6%, with average selling prices contributing 16.2%, volume and mix contributing 1.7%, and the change in foreign currency exchange rates contributing -0.3%.

•The increase in net sales within the Animal Nutrition & Health segment for the six months ended June 30, 2022 compared to 2021 was primarily the result of higher sales in monogastric markets. Total sales for this segment grew 24.9%, with average selling prices contributing 30.1%, volume and mix contributing -2.4%, and the change in foreign currency exchange rates contributing -2.8%.

•The increase in Specialty Products segment sales for the six months ended June 30, 2022 compared to 2021 was primarily due to higher sales of products in the medical device sterilization market. Total sales for this segment grew 12.8%, with average selling prices contributing 16.7%, volume and mix contributing -1.6%, and the change in foreign currency exchange rates contributing -2.3%.

•Sales relating to Other increased from the prior year due to higher demand.

Gross Margin

	Six Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Gross margin	$	143,382		$	118,174		$	25,208	21.3	%
% of net sales	30.8		%	30.5		%

Gross margin dollars increased for the six months ended June 30, 2022 compared to 2021 due to the aforementioned higher sales of $77,539, partially offset by an increase in cost of goods sold of $52,331. The 19.4% increase in cost of goods sold was mainly driven by the significant inflation of manufacturing input costs, primarily related to raw materials, partially offset by the timing of costs associated with a flash flood event at our Verona manufacturing facility in the prior year.

32

Table of Contents

Operating Expenses

	Six Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Operating expenses	$	65,126		$	57,006		$	8,120	14.2	%
% of net sales	14.0		%	14.7		%

The increase in operating expenses was primarily due to higher compensation-related costs of $4,201, an increase in advertising and marketing of $1,043, and higher travel expenses of $735.

Earnings from Operations

	Six Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Human Nutrition & Health	$	44,008		$	38,711		$	5,297	13.7	%
Animal Nutrition & Health	18,907			8,617			10,290		119.4	%
Specialty Products	17,680			16,918			762		4.5	%
Other and unallocated	(2,339)			(3,078)			739		24.0	%
Earnings from operations	$	78,256		$	61,168		$	17,088	27.9	%
% of net sales (operating margin)	16.8		%	15.8		%

•Earnings from operations for the Human Nutrition & Health segment increased primarily due to the aforementioned higher sales and a 100 basis point increase in gross margin as a percentage of sales, primarily related to the timing of costs associated with the recovery of a flash flood event at our Verona manufacturing facility in the prior year, partially offset by a significant increase in certain manufacturing input costs, largely related to raw materials. Additionally, operating expenses for this segment increased by $4,110, primarily due to higher compensation-related costs of $2,086.

•Animal Nutrition & Health segment earnings from operations increased primarily due to the aforementioned higher sales and a 530 basis point increase in gross margin as a percentage of sales primarily related to the timing of costs associated with the recovery of a flash flood event at our Verona manufacturing facility in the prior year, partially offset by a significant increase in certain manufacturing input costs, largely related to raw materials. Additionally, operating expenses for this segment increased by $1,759, primarily related to higher compensation-related costs of $932 and an increase in advertising and marketing of $505.

•The increase in earnings from operations for the Specialty Products segment was primarily due to the aforementioned higher sales, partially offset by a 250 basis point decrease in gross margin as a percentage of sales, primarily due to a significant increase in certain manufacturing input costs, largely related to raw materials.

•Earnings from operations relating to Other increased from the prior year primarily due to the aforementioned higher sales, partially offset by an increase in transaction costs, mainly related to the Kappa acquisition.

33

Table of Contents

Other Expenses (Income)

	Six Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Interest expense	$	1,505	$	1,333	$	172	12.9	%
Other, net	(137)		(167)		30		(18.0)	%
	$	1,368	$	1,166	$	202	17.3	%

Interest expense for the six months ended June 30, 2022 and 2021 was primarily related to outstanding borrowings under the 2018 Credit Agreement.  

Income Tax Expense

	Six Months Ended June 30,						Increase (Decrease)
(in thousands)	2022			2021					% Change
Income tax expense	$	18,176		$	13,860		$	4,316	31.1	%
Effective tax rate	23.6		%	23.1		%

The increase in the effective tax rate was primarily due to lower tax benefits from stock-based compensation and a reduction in certain tax credits.

FINANCIAL CONDITION

LIQUIDITY AND CAPITAL RESOURCES

(All amounts in thousands, except share and per share data)

In June 2022 we drew down an additional $345,000 from our revolving credit facility to fund the acquisition of Kappa. In connection with this transaction, the seller has an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics are met, and therefore we recorded a contingent consideration liability of kr245,000 (translated to $24,793) as of June 30, 2022. Excluding the events previously mentioned, there were no other material changes during the six months ended June 30, 2022 outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2021. We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. On July 27, 2022, we entered into an Amended and Restated Credit Agreement with a bank syndicate providing for a revolving loan of $550,000, due July 27, 2027. The revolving loan proceeds were used to pay down the existing debt under the 2018 Credit Agreement and may be used for working capital, letters of credit, and other corporate purposes. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so.

Cash

Cash and cash equivalents decreased to $76,183 at June 30, 2022 from $103,239 at December 31, 2021. At June 30, 2022, the Company had $61,390 of cash and cash equivalents held by foreign subsidiaries.  We presently intend to permanently reinvest these funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund U.S. operations or obligations. However, if these funds are needed for U.S. operations, we could be required to pay additional withholding taxes to repatriate these funds.  Working capital was $232,998 at June 30, 2022 as compared to $178,430 at December 31, 2021, an increase of $54,568. Working capital reflects the payment of the 2021 declared dividend in 2022 of $20,704, payments on the revolving loan and acquired debt of $70,648, and capital expenditures and intangible assets acquired of $20,799.

34

Table of Contents

	Six Months Ended June 30,				Increase (Decrease)
(in thousands)	2022		2021				% Change
Cash flows provided by operating activities	$	55,261	$	76,389	$	(21,128)	(27.7)	%
Cash flows used in investing activities	(316,412)		(13,520)		(302,892)		(2240.3)	%
Cash flows provided by (used in) financing activities	239,694		(65,727)		305,421		464.7	%

Operating Activities

The decrease in cash flows from operating activities was primarily driven by changes in working capital and the timing of increased sales, restocking of inventory, and payments to suppliers.

Investing Activities

As previously noted, on June 21, 2022, we completed the acquisition of Kappa, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. Cash paid for the acquisition, net of cash acquired, amounted to $295,660.

We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $20,799 and $13,760 for the six months ended June 30, 2022 and 2021, respectively.

Financing Activities

As previously noted, the acquisition of Kappa was primarily funded through the 2018 Credit Agreement. We borrowed $365,000 against the revolving loan and made total loan payments of $40,000 during the six months ended June 30, 2022, resulting in $66,431 available under the 2018 Credit Agreement as of June 30, 2022. In addition, we also made payments of $30,648 on the acquired debt related to the acquisition of Kappa.

We have an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,068,905 shares have been purchased.  We repurchase shares from employees in connection with settlement of transactions under our equity incentive plans. We also intend to acquire shares from time to time at prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors.

Proceeds from stock options exercised were $1,328 and $3,886 for the six months ended June 30, 2022 and 2021, respectively.  Dividend payments were $20,704 and $18,700 for the six months ended June 30, 2022 and 2021, respectively.

Other Matters Impacting Liquidity

We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 15 – Employee Benefit Plans.  The liability recorded in "Other long-term liabilities" on the condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021 was $1,221 and $1,293, respectively, and the plans are not funded.  Historical cash payments made under these plans have typically been less than $100 per year. We do not anticipate any changes to the payments made in the current year for the plans.

On June 1, 2018, we established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees.  Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company.  The deferred compensation liability as of June 30, 2022 and December 31, 2021 was $8,220 and $6,251, respectively, and was included in "other long-term obligations" on our balance sheet. The related rabbi trust assets were $8,255 and $6,267 as of June 30, 2022 and December 31, 2021, respectively, and were included in "other non-current assets" on the condensed consolidated balance sheets.

Chemogas has an unfunded defined benefit plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on our balance sheets as of June 30, 2022 and December 31, 2021 were $641 and $684, respectively, and were included in "other long-term obligations."

35

Table of Contents

Critical Accounting Policies

There were no changes to the Company's Critical Accounting Policies, as described in its December 31, 2021 Annual Report on Form 10-K, during the six months ended June 30, 2022.

Related Party Transactions

We were engaged in related party transactions with St. Gabriel CC Company, LLC during the three and six months ended June 30, 2022. Refer to Note 18, "Related Party Transactions".

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

Our cash and cash equivalents are held primarily in certificates of deposit and money market investment funds. In the second quarter of 2019, we entered into an interest rate swap and cross-currency swap for hedging purposes. Refer to details noted above (see Note 20, "Derivative Instruments and Hedging Activities"). Additionally, as of June 30, 2022, our borrowings were under a revolving loan bearing interest at a fluctuating rate as defined by the 2018 Credit Agreement plus an applicable rate. The applicable rate is based upon our consolidated net leverage ratio, as defined in the 2018 Credit Agreement. A 100 basis point increase or decrease in interest rates, applied to our borrowings at June 30, 2022, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately $4,336. We are exposed to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of raw material pricing arising in our business activities. We manage these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change. Additionally, as disclosed below in Part II, Item 1A, we are monitoring market risks related to the current COVID-19 pandemic very closely.

Interest Rate Risk

We have exposure to market risk for changes in interest rates, including the interest rate relating to the 2018 Credit Agreement. In the second quarter of 2019, we began to manage our interest rate exposure through the use of derivative instruments. All of our derivative instruments are utilized for risk management purposes, and are not used for trading or speculative purposes. We have hedged a portion of our floating interest rate exposure using an interest rate swap (see Note 20, "Derivative Instruments and Hedging Activities"). As of June 30, 2022, the notional amount of our outstanding interest rate swap was $108,569.

Foreign Currency Exchange Risk

The financial condition and results of operations of our foreign subsidiaries are reported in Euros, Canadian Dollars, Malaysian Ringgits, Singapore Dollars, Australian Dollars, Philippine Pesos, and Norwegian Kroner, and then translated into U.S. dollars at the applicable currency exchange rate for inclusion in our consolidated financial statements. Therefore, we are exposed to foreign currency exchange risk related to these currencies. In the second quarter of 2019, we entered into a cross-currency swap, with a notional amount of $108,569, which we designated as a hedge of our net investment in Chemogas (see Note 20, "Derivative Instruments and Hedging Activities").

On June 21, 2022, the Company completed the acquisition of Kappa. In the process of acquiring Kappa, the Company entered into four short-term foreign currency exchange forward contracts with JP Morgan Chase, N.A to manage our exposure related to changes in foreign currency exchange rates in connection with the Kappa acquisition. These contracts did not qualify for hedge accounting under the applicable sections of ASC Topic 815. For the six months ended June 30, 2022, the net gains on these forward contracts amounted to $512 and were recorded in "other (income) expense, net" on the condensed consolidated statements of earnings. As of June 30, 2022, the Company did not maintain any open foreign currency exchange forward contracts as all four contracts were settled as of June 30, 2022.

Item 4.    Controls and Procedures

(a)Evaluation of Disclosure Controls and Procedures

Prior to filing this report, we completed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act as of June 30, 2022. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2022.

(b)Changes in Internal Controls

36

Table of Contents

Except with respect to the acquisition of Kappa described below, there have been no changes in the internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

On June 21, 2022, we completed the acquisition of Kappa (See Note 2, "Significant Acquisitions"). We are integrating Kappa into our overall internal control over financial reporting process and expect to exclude the business from our assessment of internal control over financial reporting as of December 31, 2022. Total assets of the Kappa business represented approximately 24.8 % of our consolidated total assets as of June 30, 2022.

Part II.    Other Information

Item 1A.    Risk Factors

There have been no material changes in the Risk Factors identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, except as follows:

Operational Risks

Our foreign sales and operations may be adversely affected by supply chain disruptions due to political unrest, terrorist acts, and national and international conflict, including Russia's invasion of Ukraine. .

We conduct a portion of our sales and manufacturing outside the United States. Our foreign sales and operations are subject to a number of risks, including political and economic instability, which could have a material adverse impact on our ability to increase or maintain our international sales and operations. National and international conflicts such as war, border closures, civil disturbances and terrorist acts, including Russia's invasion of Ukraine, may increase the likelihood of already strained supply interruptions and further hinder our ability to access the materials and energy we need to manufacture our products. Additional supply chain disruptions will make it harder for us to find favorable pricing and reliable sources for the materials we need. As a result, such disruptions will put upward pressure on our costs and increase the risk that we may be unable to acquire the materials and services we need to continue to make certain products, in particular at our manufacturing facilities in Europe.

Item 2C.     Issuer Purchase of Equity Securities

The following table summarizes the share repurchase activity for the six months ended June 30, 2022:

	Total Number of Shares Purchased (1)	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs (1)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
January 1-31, 2022	88,154	$	147.03	88,154	$	125,951,395
February 1-28, 2022	57,531	$	139.75	57,531	$	111,675,367
March 1-31, 2022	100,000	$	135.98	100,000	$	95,065,135
First Quarter	245,685			245,685
April 1-30, 2022	245	$	125.36	245	$	87,609,591
May 1-31, 2022	4,550	$	120.01	4,550	$	83,324,693
June 1-30, 2022	181	$	125.87	181	$	83,370,521
Second Quarter	4,976			4,976
Total	250,661			250,661
(1) Our Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,068,905 shares have been purchased. There is no expiration for this program.

37

Table of Contents

Item 6.    Exhibits

Exhibit Number	Description
Exhibit 31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
Exhibit 32.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

38

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BALCHEM CORPORATION
	By: /s/ Theodore L. Harris
	Theodore L. Harris, Chairman, President and Chief Executive Officer
	By: /s/ Martin Bengtsson
	Martin Bengtsson, Chief Financial Officer and Treasurer
Date: July 29, 2022

39

EX-31.1

Exhibit 31.1 

CERTIFICATIONS 

I, Theodore L. Harris, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Balchem Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 29, 2022	/s/ Theodore L. Harris
	Theodore L. Harris
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2

Exhibit 31.2 

CERTIFICATIONS 

I, Martin Bengtsson, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Balchem Corporation;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 29, 2022	/s/ Martin Bengtsson
	Martin Bengtsson
	Chief Financial Officer and Treasurer
	(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Balchem Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Theodore L. Harris, President, and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Theodore L. Harris

Theodore L. Harris

President and

Chief Executive Officer

(Principal Executive Officer)

July 29, 2022

This certification accompanies the above-described Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Balchem Corporation (the "Company") on Form 10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Martin Bengtsson, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Martin Bengtsson

Martin Bengtsson

Chief Financial Officer and Treasurer

(Principal Financial Officer)

July 29, 2022

This certification accompanies the above-described Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. 

XML

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Jul. 21, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	1-13648
Entity Registrant Name	Balchem Corporation
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	13-2578432
Entity Address, Address Line One	52 Sunrise Park Road
Entity Address, City or Town	New Hampton
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10958
City Area Code	845
Local Phone Number	326-5600
Title of 12(b) Security	Common Stock, par value $.06-2/3 per share
Trading Symbol	BCPC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,120,593
Entity Central Index Key	0000009326
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 76,183	$ 103,239
Accounts receivable, net of allowance for doubtful accounts of $1,203 and $928 at June 30, 2022 and December 31, 2021 respectively	138,579	117,408
Inventories	140,840	91,058
Prepaid expenses	8,467	6,116
Derivative assets	7,276	0
Other current assets	5,796	4,411
Total current assets	377,141	322,232
Property, plant and equipment, net	252,145	237,517
Goodwill	731,772	523,949
Intangible assets with finite lives, net	218,802	94,665
Right of use assets - operating leases	10,718	6,929
Right of use assets - finance lease	2,255	2,359
Other assets	13,841	11,674
Total assets	1,606,674	1,199,325
Current liabilities:
Trade accounts payable	66,363	56,243
Accrued expenses	58,649	43,411
Accrued compensation and other benefits	14,973	19,567
Dividends payable	127	20,886
Income taxes payable	863	1,334
Operating lease liabilities - current	2,997	2,194
Finance lease liabilities - current	171	167
Total current liabilities	144,143	143,802
Revolving loan	433,569	108,569
Deferred income taxes	77,574	46,455
Operating lease liabilities - non-current	7,725	4,811
Finance lease liabilities - non-current	2,216	2,303
Derivative liabilities	0	2,658
Contingent consideration liability	24,793	0
Other long-term obligations	15,284	13,712
Total liabilities	705,304	322,310
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $0.0667 par value. Authorized 120,000,000 shares; 32,120,593 and 32,287,150 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	2,143	2,154
Additional paid-in capital	120,811	147,716
Retained earnings	790,840	732,138
Accumulated other comprehensive income	(12,424)	(4,993)
Total stockholders' equity	901,370	877,015
Total liabilities and stockholders' equity	$ 1,606,674	$ 1,199,325

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Allowance for doubtful accounts	$ 1,203	$ 928
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0667	$ 0.0667
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,120,593	32,287,150
Common stock, shares outstanding (in shares)	32,120,593	32,287,150

XML

Condensed Consolidated Statements of Earnings - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net sales	$ 236,693	$ 202,365	$ 465,560	$ 388,021
Cost of sales	164,817	142,918	322,178	269,847
Gross margin	71,876	59,447	143,382	118,174
Operating expenses:
Selling expenses	15,991	14,846	32,976	29,770
Research and development expenses	2,922	2,899	6,153	5,648
General and administrative expenses	13,043	11,109	25,997	21,588
Total operating expenses	31,956	28,854	65,126	57,006
Earnings from operations	39,920	30,593	78,256	61,168
Other expenses, net:
Interest expense, net	960	608	1,505	1,333
Other (income) expense, net	(298)	(34)	(137)	(167)
Total other expenses (income)	662	574	1,368	1,166
Earnings before income tax expense	39,258	30,019	76,888	60,002
Income tax expense	9,476	7,288	18,176	13,860
Net earnings	$ 29,782	$ 22,731	$ 58,712	$ 46,142
Net earnings per common share - basic (in dollars per share)	$ 0.93	$ 0.71	$ 1.83	$ 1.43
Net earnings per common share - diluted (in dollars per share)	$ 0.92	$ 0.70	$ 1.81	$ 1.41

XML

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 29,782	$ 22,731	$ 58,712	$ 46,142
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(6,951)	1,524	(9,793)	(4,619)
Unrealized gain on cash flow hedge	850	351	2,423	863
Change in postretirement benefit plans	(34)	8	(61)	15
Other comprehensive income (loss)	(6,135)	1,883	(7,431)	(3,741)
Comprehensive income	$ 23,647	$ 24,614	$ 51,281	$ 42,401

XML

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock	Additional Paid-in Capital
Beginning balance at Dec. 31, 2020	$ 828,233	$ 656,740	$ 4,173	$ 2,160	$ 165,160
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,372,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	23,411	23,411
Other comprehensive income (loss)	(5,624)		(5,624)
Repurchases of common stock	(1,596)			$ (1)	(1,595)
Repurchases of common stock (in shares)				(13,475)
Shares and options (cancelled) issued under stock plans (in shares)				92,784
Shares and options issued under stock plans	5,068			$ 6	5,062
Ending balance at Mar. 31, 2021	849,492	680,151	(1,451)	$ 2,165	168,627
Ending balance, common stock (in shares) at Mar. 31, 2021				32,451,930
Beginning balance at Dec. 31, 2020	828,233	656,740	4,173	$ 2,160	165,160
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,372,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	46,142
Other comprehensive income (loss)	(3,741)
Ending balance at Jun. 30, 2021	869,642	702,882	432	$ 2,162	164,166
Ending balance, common stock (in shares) at Jun. 30, 2021				32,404,774
Beginning balance at Mar. 31, 2021	849,492	680,151	(1,451)	$ 2,165	168,627
Beginning balance, common stock (in shares) at Mar. 31, 2021				32,451,930
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	22,731	22,731
Other comprehensive income (loss)	1,883		1,883
Repurchases of common stock	(9,240)			$ (5)	(9,235)
Repurchases of common stock (in shares)				(72,649)
Shares and options (cancelled) issued under stock plans (in shares)				25,493
Shares and options issued under stock plans	4,776			$ 2	4,774
Ending balance at Jun. 30, 2021	869,642	702,882	432	$ 2,162	164,166
Ending balance, common stock (in shares) at Jun. 30, 2021				32,404,774
Beginning balance at Dec. 31, 2021	877,015	732,138	(4,993)	$ 2,154	147,716
Beginning balance, common stock (in shares) at Dec. 31, 2021				32,287,150
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	28,930	28,930
Other comprehensive income (loss)	(1,296)		(1,296)
Repurchases of common stock	(34,599)			$ (16)	(34,583)
Repurchases of common stock (in shares)				(245,685)
Dividends	(10)	(10)
Shares and options (cancelled) issued under stock plans (in shares)				74,604
Shares and options issued under stock plans	3,642			$ 4	3,638
Ending balance at Mar. 31, 2022	873,682	761,058	(6,289)	$ 2,142	116,771
Ending balance, common stock (in shares) at Mar. 31, 2022				32,116,069
Beginning balance at Dec. 31, 2021	877,015	732,138	(4,993)	$ 2,154	147,716
Beginning balance, common stock (in shares) at Dec. 31, 2021				32,287,150
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	58,712
Other comprehensive income (loss)	(7,431)
Ending balance at Jun. 30, 2022	901,370	790,840	(12,424)	$ 2,143	120,811
Ending balance, common stock (in shares) at Jun. 30, 2022				32,120,593
Beginning balance at Mar. 31, 2022	873,682	761,058	(6,289)	$ 2,142	116,771
Beginning balance, common stock (in shares) at Mar. 31, 2022				32,116,069
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	29,782	29,782
Other comprehensive income (loss)	(6,135)		(6,135)
Repurchases of common stock	(600)				(600)
Repurchases of common stock (in shares)				(4,976)
Shares and options (cancelled) issued under stock plans (in shares)				9,500
Shares and options issued under stock plans	4,641			$ 1	4,640
Ending balance at Jun. 30, 2022	$ 901,370	$ 790,840	$ (12,424)	$ 2,143	$ 120,811
Ending balance, common stock (in shares) at Jun. 30, 2022				32,120,593

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net earnings	$ 58,712	$ 46,142
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	23,861	24,463
Stock compensation expense	6,889	5,914
Deferred income taxes	1,778	54
Provision for doubtful accounts	380	(25)
Unrealized loss/(gain) on foreign currency transaction and deferred compensation	188	(401)
Asset impairment charge	23	0
Loss/(gain) on disposal of assets	203	(19)
Changes in assets and liabilities
Accounts receivable	(15,506)	(16,361)
Inventories	(33,141)	(7,949)
Prepaid expenses and other current assets	(1,733)	(2,859)
Accounts payable and accrued expenses	15,075	25,873
Income taxes	(779)	898
Other	(689)	659
Net cash provided by operating activities	55,261	76,389
Cash flows from investing activities:
Cash paid for acquisition, net of cash acquired	(295,660)	0
Capital expenditures and intangible assets acquired	(20,799)	(13,760)
Proceeds from sale of assets	197	240
Investment in affiliates	(150)	0
Net cash used in investing activities	(316,412)	(13,520)
Cash flows from financing activities:
Proceeds from revolving loan	365,000	5,000
Principal payments on revolving loan	(40,000)	(45,000)
Principal payments on acquired debt	(30,648)	0
Principal payments on finance lease	(83)	(78)
Proceeds from stock options exercised	1,328	3,886
Dividends paid	(20,704)	(18,700)
Purchase of common stock	(35,199)	(10,835)
Net cash provided by (used in) financing activities	239,694	(65,727)
Effect of exchange rate changes on cash	(5,599)	(1,811)
Decrease in cash and cash equivalents	(27,056)	(4,669)
Cash and cash equivalents beginning of period	103,239	84,571
Cash and cash equivalents end of period	$ 76,183	$ 79,902

XML

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The condensed consolidated financial statements presented herein have been prepared in accordance with the accounting policies described in the December 31, 2021 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements reflect the operations of Balchem Corporation and its subsidiaries (the "Company"). All intercompany balances and transactions have been eliminated in consolidation.

In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal, recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 (the "Exchange Act") and therefore do not include some information and notes necessary to conform to annual reporting requirements. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results expected for the full year or any interim period.

Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted the Standard Update in 2021. The adoption of the Standard update did not have a significant impact on the Company's consolidated financial statements and disclosures.

In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on the Company's consolidated financial statements and disclosures.

XML

SIGNIFICANT ACQUISITIONS

6 Months Ended

Jun. 30, 2022

Business Combination and Asset Acquisition [Abstract]

SIGNIFICANT ACQUISITIONS

SIGNIFICANT ACQUISITIONS

On June 21, 2022, Balchem and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies being hereinafter collectively referred to as “Kappa”). The Company made payments of approximately kr3,301,341 ("kr" indicates the Norwegian krone) on the acquisition date, amounting to approximately kr2,997,669 to the former shareholder and approximately kr303,672 to Kappa's lenders to pay off all Kappa bank debt. Net of cash acquired of kr63,064, total payments on the acquisition date were kr3,238,277. Considering net cash acquired of $6,365, these payments translated to approximately $326,820 paid on the acquisition date, amounting to $302,537 paid to the former shareholder and approximately $30,648 to Kappa's lenders. The acquisition was primarily financed through the 2018 Credit Agreement (see Note 8, "Revolving Loan"). In connection with this transaction, the seller has an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics are met, and therefore we recorded contingent consideration of kr245,000 (translated to $24,793) as of June 30, 2022. Kappa manufactures specialty vitamin K2, a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. Kappa's K2VITAL® branded vitamin K2 is the leading synthetic vitamin K2 and is backed by strong intellectual property and a deep clinical research portfolio. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition & Health segment.

The goodwill of $212,591 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Human Nutrition & Health business segment and is not deductible for income tax purposes.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:

Cash and cash equivalents	$	6,365
Accounts receivable	8,036
Inventories	17,701
Property, plant and equipment	9,854
Right of use assets	3,349
Customer relationships	113,545
Developed technology	18,166
Trademarks	6,055
Other assets	2,399
Accounts payable	(3,301)
Bank debt	(30,648)
Lease liabilities	(3,349)
Other liabilities	(4,373)
Deferred income taxes, net	(29,127)
Goodwill	212,591
Total consideration on acquisition date	327,263
Contingent consideration liability	(24,726)
Net gains on foreign currency exchange forward contracts	(512)
Amount paid to shareholders	302,025
Kappa bank debt paid on purchase date	30,648
Total amount paid on acquisition date	$	332,673

The estimated fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions, which are subject to change. In preparing our preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration. The purchase price and related allocation of assets acquired and liabilities assumed is preliminary pending management's final review of fair value calculations and deferred tax liabilities related to certain non-deductible assets.

Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined.

Transaction and integration costs related to the Kappa acquisition are included in selling, general, and administrative expenses and were $451 for both the three and six months ended June 30, 2022. There were no such amounts related to this acquisition for the three and six months ended June 30, 2021.

The following preliminary unaudited pro forma information has been prepared as if the acquisition had occurred on January 1, 2021.

	Three Months Ended June 30,				Six Months Ended June 30,
	Net Sales		Net Earnings		Net Sales		Net Earnings
Kappa actual results included in the Company's consolidated income statement from June 21, 2022 through June 30, 2022	$	—	$	—	$	—	$	—
2022 Supplemental pro forma combined financial information	$	247,430	$	30,172	$	489,170	$	58,648
2021 Supplemental pro forma combined financial information	$	213,032	$	26,344	$	410,649	$	50,379

Kappa's net sales and net earnings from June 21, 2022 through June 30, 2022 were not material. As such, they were not included in the Company's condensed consolidated statements of earnings for the three and six months ended June 30, 2022. 2022 supplemental pro forma net earnings for the three and six months ended June 30, 2022, excluded $643 and $722, respectively, of acquisition-related costs incurred. The pro forma information presented does not purport to be indicative of the results that actually would have been attained if the Kappa acquisition had occurred at the beginning of the periods presented, and is not intended to be a projection of future results.

XML

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2022

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

STOCK-BASED COMPENSATION

The Company’s results for the three and six months ended June 30, 2022 and 2021 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

	Increase/(Decrease) for the				Increase/(Decrease) for the
	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cost of sales	$	277	$	444	$	676	$	744
Operating expenses	3,535		2,849		6,213		5,170
Net earnings	(2,933)		(2,547)		(5,312)		(4,569)

As allowed by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest.

The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of June 30, 2022, the plans had 534,120 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three to four years for employee restricted stock awards, three years for employee

performance share awards, and three years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events.

Option activity for the six months ended June 30, 2022 and 2021 is summarized below:

For the six months ended June 30, 2022	Shares (000s)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2021	867	$	88.19	$	69,711
Granted	109	138.07
Exercised	(18)	72.74
Forfeited	(6)	120.36
Canceled	—	—
Outstanding as of June 30, 2022	952	$	93.99	$	34,907	6.4
Exercisable as of June 30, 2022	666	$	81.11	$	32,409	5.4

For the six months ended June 30, 2021	Shares (000s)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2020	858	$	80.58	$	29,735
Granted	129	119.12
Exercised	(58)	65.95
Forfeited	(2)	101.38
Canceled	(1)	74.57
Outstanding as of June 30, 2021	926	$	86.85	$	41,107	6.8
Exercisable as of June 30, 2021	580	$	73.72	$	33,398	5.6

ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.5% and 0.5%; expected volatilities of 31% and 33%; risk-free interest rates of 2.0% and 0.5%; and expected lives of 4.9 years and 4.9 years, in each case for the six months ended June 30, 2022 and 2021, respectively.

The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury Zero coupon issues with a remaining term equal to the expected life.

Other information pertaining to option activity during the three and six months ended June 30, 2022 and 2021 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Weighted-average fair value of options granted	$	—	$	34.42	$	40.26	$	33.11
Total intrinsic value of stock options exercised ($000s)	$	495	$	1,814	$	1,149	$	3,731

Non-vested restricted stock activity for the six months ended June 30, 2022 and 2021 is summarized below:

	Six Months Ended June 30,
	2022			2021
	Shares (000s)	Weighted Average Grant Date Fair Value		Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31	166	$	99.70	159	$	90.71
Granted	34	137.74		37	119.30
Vested	(77)	80.84		(13)	87.33
Forfeited	(3)	116.73		(2)	85.60
Non-vested balance as of June 30	120	$	122.03	181	$	96.89

Non-vested performance share activity for the six months ended June 30, 2022 and 2021 is summarized below:

	Six Months Ended June 30,
	2022			2021
	Shares (000s)	Weighted Average Grant Date Fair Value		Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31	69	$	110.72	71	$	91.99
Granted	39	114.22		36	108.74
Vested	(35)	53.17		(24)	70.64
Forfeited	(3)	84.09		(11)	74.57
Non-vested balance as of June 30	70	$	127.69	72	$	110.22

The performance share (“PS”) awards provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and relative total shareholder return (TSR) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 1.8% and 0.2%; dividend yields of 0.5% and 0.6%; volatilities of 32% and 33%; and initial TSR’s of -15.7% and 11.7%, in each case for the six months ended June 30, 2022 and 2021, respectively. Expense is estimated based on the number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved.  The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth.

As of June 30, 2022 and 2021, there were $19,988 and $19,796, respectively, of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the plans. As of June 30, 2022, the unrecognized

compensation cost is expected to be recognized over a weighted-average period of approximately 1.7 years. The Company estimates that share-based compensation expense for the year ended December 31, 2022 will be approximately $13,000.

REPURCHASE OF COMMON STOCK

The Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,068,905 shares have been purchased. The Company’s prior presentation of reflecting treasury stock separately within stockholders’ equity has been adjusted to conform to the presentation prescribed by the State of Maryland, where the Company is incorporated. In connection therewith, adjustments to balances previously reflected as treasury stock of $8,472, $2,210, and $7,873 as of June 30, 2021, March 31, 2021, and December 31, 2020, respectively, were made to the condensed consolidated statements of changes in stockholders’ equity and prior references to “Treasury shares purchased” were updated to “Repurchases of common stock”, accordingly. There was no impact to total stockholders’ equity in any of the years presented as a result of these updates. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. During the six months ended June 30, 2022 and 2021, the Company purchased 250,661 and 86,124 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $140.42 and $125.81, respectively.

XML

INVENTORIES

6 Months Ended

Jun. 30, 2022

Inventory Disclosure [Abstract]

INVENTORIES

INVENTORIES

Inventories at June 30, 2022 and December 31, 2021 consisted of the following:

	June 30, 2022		December 31, 2021
Raw materials	$	43,342	$	28,639
Work in progress	20,249		10,563
Finished goods	77,249		51,856
Total inventories	$	140,840	$	91,058

XML

PROPERTY, PLANT AND EQUIPMENT

6 Months Ended

Jun. 30, 2022

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at June 30, 2022 and December 31, 2021 are summarized as follows:

	June 30, 2022		December 31, 2021
Land	$	11,273	$	11,692
Building	91,140		89,602
Equipment	263,929		253,995
Construction in progress	65,906		52,930
	432,248		408,219
Less: accumulated depreciation	180,103		170,702
Property, plant and equipment, net	$	252,145	$	237,517

XML

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

INTANGIBLE ASSETSThe Company had goodwill in the amount of $731,772 and $523,949 as of June 30, 2022 and December 31, 2021, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The increase in goodwill is the result of the acquisition of Kappa, partially offset by the change due to foreign exchange translation adjustments. Refer to Note 2, "Significant Acquisitions", for more information.

Identifiable intangible assets with finite lives at June 30, 2022 and December 31, 2021 are summarized as follows:

	Amortization Period (in years)	Gross Carrying Amount at 6/30/2022		Accumulated Amortization at 6/30/2022		Gross Carrying Amount at 12/31/2021		Accumulated Amortization at 12/31/2021
Customer relationships & lists	10-20	$	350,523	$	180,638	$	240,059	$	173,489
Trademarks & trade names	2-17	48,724		30,968		43,116		28,985
Developed technology	5-12	38,252		14,993		20,234		14,607
Other	2-18	24,687		16,785		23,921		15,584
		$	462,186	$	243,384	$	327,330	$	232,665

Amortization of identifiable intangible assets was approximately $5,850 and $11,761 for the three and six months ended June 30, 2022, respectively, and $6,229 and $12,713 for the three and six months ended June 30, 2021, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, estimated amortization expense is $14,485 for the remainder of 2022, $27,923 for 2023, $19,659 for 2024, $16,117 for 2025, $15,710 for 2026 and $14,949 for 2027. At June 30, 2022 and December 31, 2021, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in “Intangible assets with finite lives, net” in the Company’s condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the six months ended June 30, 2022 and 2021.

XML

EQUITY-METHOD INVESTMENT	6 Months Ended
	Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
EQUITY-METHOD INVESTMENT	EQUITY-METHOD INVESTMENTIn 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company receives up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance.  The Company recognized a loss of $140 and $280 for the three and six months ended June 30, 2022, respectively, and $130 and $274 for the three and six months ended June 30, 2021, respectively, relating to its portion of the joint venture's expenses in other expense. The Company made capital contributions to the investment totaling $75 and $133 for the three and six months ended June 30, 2022, respectively, and received a net return of capital totaling $28 and $15 for the three and six months ended June 30, 2021, respectively. The carrying value of the joint venture at June 30, 2022 and December 31, 2021 was $4,352 and $4,499, respectively, and is recorded in "Other assets."

XML

REVOLVING LOAN

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

REVOLVING LOAN

REVOLVING LOANOn June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "2018 Credit Agreement"), which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000.  The 2018 Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”).  The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion.  The initial proceeds from the 2018 Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. During the second quarter of 2022, the Company borrowed an additional $345,000 to fund the Kappa acquisition (see Note 2, "Significant Acquisitions"). As of June 30, 2022 and December 31, 2021, the total balance outstanding on the 2018 Credit Agreement amounted to $433,569 and $108,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. On July 27, 2022, the Company entered into an Amended and Restated Credit Agreement with lenders in the form of a senior secured revolving credit facility, due July 27, 2027. The Amended and Restated Credit Agreement allows for up to $550,000 of borrowing. The Company used initial proceeds from the Amended and Restated Credit Agreement to repay the outstanding balance of $433,569 on the previous revolving credit facility, due June 2023. In connection with the entering into the Amended and Restated Credit Agreement, the Company also modified its existing interest rate swap under the relief provided for in ASC 848, "Reference Rate Reform" (see Note 20 "Derivative Instruments and Hedging Activities").

Amounts outstanding under the 2018 Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the 2018 Credit Agreement plus an applicable rate.  The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the 2018 Credit Agreement, and the interest rate was 2.538% at June 30, 2022. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the 2018 Credit Agreement and ranges from 0.15% to 0.275% (0.15% at June 30, 2022).  The unused portion of the revolving loan amounted to $66,431 at June 30, 2022.  The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders.

Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the 2018 Credit Agreement, which is not materially different than the effective interest method.  Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $280 and $421 at June 30, 2022 and December 31, 2021, respectively, and are included in other assets on the condensed consolidated balance sheets. Amortization expense pertaining to these costs totaled $70 and $141 for the three and six months ended June 30, 2022 and 2021, respectively, and are included in "Interest expense" in the accompanying condensed consolidated statements of earnings.

The 2018 Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio.  At June 30, 2022, the Company was in compliance with these covenants.  Indebtedness under the Company’s loan agreements is secured by assets of the Company.

XML

NET EARNINGS PER SHARE

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

NET EARNINGS PER SHARE

NET EARNINGS PER SHARE

The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net Earnings - Basic and Diluted	$	29,782	$	22,731	$	58,712	$	46,142
Shares (000s)
Weighted Average Common Shares - Basic	31,999		32,232		32,020		32,243
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares	315		419		375		410
Weighted Average Common Shares - Diluted	32,314		32,651		32,395		32,653
Net Earnings Per Share - Basic	$	0.93	$	0.71	$	1.83	$	1.43
Net Earnings Per Share - Diluted	$	0.92	$	0.70	$	1.81	$	1.41

The number of anti-dilutive shares were 294,568 and 237,453 for the three and six months ended June 30, 2022, respectively, and 153,868 and 304,324 for the three and six months ended June 30, 2021, respectively. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.

XML

INCOME TAXES

6 Months Ended

Jun. 30, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The Company’s effective tax rate for the three months ended June 30, 2022 and 2021, was 24.1% and 24.3%, respectively, and 23.6% and 23.1% for the six months ended June 30, 2022 and 2021. The decrease in the effective tax rate for the three months ended June 30, 2022 compared to the three months ended June 30, 2021 was primarily due to the prior year being negatively impacted by clarifying regulations related to tax reform, which was offset by lower tax benefits from stock-based compensation in the current quarter. The increase in the effective tax rate for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 was primarily due to lower tax benefits from stock-based compensation and a reduction in certain tax credits.

Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the Securities and Exchange Commission ("SEC"), and/or the Financial Accounting Standards Board ("FASB") regarding this act.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are

measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences.

The Company accounts for uncertainty in income taxes utilizing ASC 740-10, "Income Taxes". ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. It prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken. This interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosures. The application of ASC 740-10 requires judgment related to the uncertainty in income taxes and could impact our effective tax rate.

The Company files income tax returns in the U.S. and in various states and foreign countries. As of June 30, 2022, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2017. As of June 30, 2022 and December 31, 2021, the Company had approximately $5,902 and $5,881, respectively, of unrecognized tax benefits, which are included in "Other long-term obligations" on the Company’s condensed consolidated balance sheets. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of "Income tax expense" in the condensed consolidated statements of earnings. The total amounts of accrued interest and penalties related to uncertain tax positions at June 30, 2022 and December 31, 2021 were approximately $2,214 and $2,106, respectively, and are included in "Other long-term obligations."

XML

SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated."

Human Nutrition & Health

The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Through the Kappa acquisition, this segment recently began manufacturing specialty vitamin K2, which is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance.

Animal Nutrition & Health

The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine

industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity.

Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace.

Specialty Products

Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. The Company’s 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.

The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment.

The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life.  First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances.

The segment information is summarized as follows:

Business Segment Assets	June 30, 2022		December 31, 2021
Human Nutrition & Health	$	1,146,749	$	727,131
Animal Nutrition & Health	171,605		158,971
Specialty Products	179,573		184,628
Other and Unallocated (1)	108,747		128,595
Total	$	1,606,674	$	1,199,325

Business Segment Net Sales	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	131,628	$	111,471	$	254,073	$	215,987
Animal Nutrition & Health	62,600		54,481		131,942		105,629
Specialty Products	36,647		34,022		69,981		62,030
Other and Unallocated (2)	5,818		2,391		9,564		4,375
Total	$	236,693	$	202,365	$	465,560	$	388,021

Business Segment Earnings Before Income Taxes	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	23,705	$	19,021	$	44,008	$	38,711
Animal Nutrition & Health	7,586		3,561		18,907		8,617
Specialty Products	9,919		9,729		17,680		16,918
Other and Unallocated (2)	(1,290)		(1,718)		(2,339)		(3,078)
Interest and other expense	(662)		(574)		(1,368)		(1,166)
Total	$	39,258	$	30,019	$	76,888	$	60,002

Depreciation/Amortization	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	7,392	$	7,441	$	14,747	$	15,014
Animal Nutrition & Health	1,668		1,816		3,329		3,580
Specialty Products	1,899		2,085		3,831		4,354
Other and Unallocated (2)	974		757		1,954		1,515
Total	$	11,933	$	12,099	$	23,861	$	24,463

Capital Expenditures	Six Months Ended June 30,
	2022		2021
Human Nutrition & Health	$	11,006	$	8,883
Animal Nutrition & Health	6,559		2,729
Specialty Products	2,206		1,448
Other and Unallocated (2)	338		66
Total	$	20,109	$	13,126

(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.

(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $872 and $1,176 for the three and six months ended June 30, 2022, respectively, and $466 and $700 for the three and six months ended June 30, 2021, respectively, and (ii) Unallocated amortization expense of $811 and $1,620 for the three and six months ended June 30, 2022, respectively, and $674 and $1,349 for the three and six months ended June 30, 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that were included in interest expense in the Company's condensed consolidated statements of earnings.

XML

REVENUE

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

REVENUE

REVENUE

Revenue Recognition

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to realize in exchange for those goods.

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product Sales	$	225,260	$	193,122	$	443,313	$	369,110
Co-manufacturing	9,819		6,878		18,126		14,156
Consignment	989		1,380		2,580		2,431
Product Sales Revenue	236,068		201,380		464,019		385,697
Royalty Revenue	625		985		1,541		2,324
Total Revenue	$	236,693	$	202,365	$	465,560	$	388,021

The following table presents revenues disaggregated by geography, based on the shipping addresses of customers:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	169,076	$	147,188	$	343,567	$	285,039
Foreign Countries	67,617		55,177		121,993		102,982
Total Revenue	$	236,693	$	202,365	$	465,560	$	388,021

Product Sales Revenues

The Company’s primary operation is the manufacturing and sale of health and nutrition ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of three sub-streams: product sales, co-manufacturing, and consignment.

Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials.  The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer.  Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided.

Royalty Revenues

Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment.

Contract Liabilities

The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable.

The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer.

Practical Expedients and Exemptions

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.

XML

SUPPLEMENTAL CASH FLOW INFORMATION

6 Months Ended

Jun. 30, 2022

Supplemental Cash Flow Information [Abstract]

SUPPLEMENTAL CASH FLOW INFORMATION

SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid during the six months ended June 30, 2022 and 2021 for income taxes and interest is as follows:

	Six Months Ended June 30,
	2022		2021
Income taxes	$	15,562	$	12,493
Interest	$	1,960	$	2,452

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

6 Months Ended

Jun. 30, 2022

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The changes in accumulated other comprehensive (loss)/income were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net foreign currency translation adjustment	$	(6,951)	$	1,524	$	(9,793)	$	(4,619)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized gain on cash flow hedge	1,122		456		3,206		1,133
Tax	(272)		(105)		(783)		(270)
Net of tax	850		351		2,423		863
Net change in postretirement benefit plan (see Note 15 for further information)
Amortization of prior service cost	2		19		4		37
Amortization of gain	—		(7)		—		(12)
Gain arising during the period and prior service credit	(9)		—		(41)		(4)
Total before tax	(7)		12		(37)		21
Tax	(27)		(4)		(24)		(6)
Net of tax and adjustment	(34)		8		(61)		15
Total other comprehensive (loss)/income	$	(6,135)	$	1,883	$	(7,431)	$	(3,741)

Included in "Net foreign currency translation adjustment" were gains of $3,963 and $5,086, related to a net investment hedge, which were net of taxes of $1,309 and $1,642 for the three and six months ended June 30, 2022, respectively. Included in "Net foreign currency translation adjustment" was a loss of $1,024 and a gain of $2,173, related to a net investment hedge, which were net of taxes of $336 and $690 for the three and six months ended June 30, 2021, respectively. See Note 20, "Derivative Instruments and Hedging Activities."

Accumulated other comprehensive (loss)/income at June 30, 2022 and December 31, 2021 consisted of the following:

	Foreign currency translation adjustment		Cash flow hedge		Postretirement benefit plan		Total
Balance December 31, 2021	$	(3,602)	$	(1,631)	$	240	$	(4,993)
Other comprehensive (loss)/income	(9,793)		2,423		(61)		(7,431)
Balance June 30, 2022	$	(13,395)	$	792	$	179	$	(12,424)

XML

EMPLOYEE BENEFIT PLANS

6 Months Ended

Jun. 30, 2022

Retirement Benefits [Abstract]

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS

Defined Contribution Plans

The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1st, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. On June 21, 2022, the Company completed the acquisition of Kappa, which sponsors one defined contribution plan for its employees.

Postretirement Medical Plans

The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona facility and a plan for those named as executive officers in the Company’s proxy statement.

Net periodic benefit costs for such retirement medical plans were as follows:

	Six Months Ended June 30,
	2022		2021
Service cost	$	39	$	43
Interest cost	13		12
Amortization of prior service cost	4		37
Amortization of gain	—		(12)
Net periodic benefit cost	$	56	$	80

The amounts recorded for these obligations on the Company’s condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021 are $1,221 and $1,293, respectively, and are included in "Other long-term obligations." These plans are unfunded and approved claims are paid from Company funds. Historical cash payments made under such plans have typically been less than $200 per year.

Defined Benefit Pension Plans

On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amounts recorded for these obligations on the Company's condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021 were $641 and $684, respectively, and were included in "Other long-term obligations."

Net periodic benefit costs for such benefit pensions plans were as follows:

	Six Months Ended June 30,
	2022		2021
Service cost with interest to end of year	$	29	$	35
Interest cost	12		7
Expected return on plan assets	(25)		(18)
Amortization of gain	—		2
Total net periodic benefit cost	$	16	$	26

Deferred Compensation Plan

On June 1, 2018, the Company established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees.  Assets of the plan are held in a rabbi trust, and are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company.  The deferred compensation liability was $8,252 as of June 30, 2022, of which $8,220 was included in "Other long-term obligations" and $32 was included in "Accrued compensation and other benefits" on the Company's condensed consolidated balance sheets. The deferred compensation liability was $6,270 as of December 31, 2021, of which $6,251 was included in "Other long-term obligations" and $19 was included in "Accrued compensation and other benefits" on the Company’s condensed consolidated balance sheets. The related rabbi trust assets were $8,255 and $6,267 as of June 30, 2022 and December 31, 2021, respectively, and were included in "Other non-current assets" on the Company's condensed consolidated balance sheets.

XML

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at June 30, 2022 are as follows:

Year
July 1, 2022 to December 31, 2022	$	1,896
2023	3,551
2024	3,754
2025	2,824
2026	2,451
2027	2,093
Thereafter	6,225
Total minimum lease payments	$	22,794

The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for certain potential liabilities associated with the Superfund site. In February 2022, BCP Ingredients, Inc. ("BCP"), the Company subsidiary that operates the site, along with the prior owner of the site received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study ("RI/FS") at the site with regard to the presence of certain contaminants at the site, focusing primarily on the presence of 1,4 dioxane and chlorobenzene. BCP and the site's prior owner are currently negotiating with the EPA and the State of Missouri with respect to a proposed Administrative Settlement Agreement and Order on Consent that defines the scope and performance of the focused RI/FS.

From time to time, the Company is a party to various litigation, claims and assessments.  Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

XML

FAIR VALUE OF FINANCIAL INSTRUMENTS

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE OF FINANCIAL INSTRUMENTS

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at June 30, 2022 and December 31, 2021 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio.  The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at June 30, 2022 and December 31, 2021 includes $927 and $933 in money market funds, respectively.

Non-current assets at June 30, 2022 and December 31, 2021 includes $8,255 and $6,267, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.”

The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in "Derivative assets" or "Derivative liabilities" in the Company's condensed consolidated balance sheets (see Note 20, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The derivative assets related to the cross-currency swap and the interest rate swap were $6,228 and $1,048 at June 30, 2022, respectively. The derivative liability related to the cross-currency swap and the interest rate swap was $500 and $2,158 at December 31, 2021, respectively.

XML

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the condensed consolidated statements of earnings. Payments for the services the Company provided amounted to $1,022 and $1,997 for the three and six months ended June 30, 2022, respectively, and $920 and $1,747 for the three and six months ended June 30, 2021, respectively. The raw materials purchased and subsequently sold amounted to $10,910 and $20,221 for the three and six months ended June 30, 2022, respectively, and $6,580 and $12,042 for the three and six months ended June 30, 2021, respectively. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $8,233 and $14,722 for the three and six months ended June 30, 2022, respectively, and $5,210 and $9,601 for the three and six months ended June 30, 2021, respectively. At June 30, 2022 and December 31, 2021, the Company had receivables of $8,224 and $10,504, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold. The Company also had payables of $5,829 and $7,552, respectively, recorded in accounts payable for finished goods received from St. Gabriel CC Company, LLC. In addition, the Company had receivables in the amount of $164 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of December 31, 2021. There were no such receivables as of June 30, 2022. The Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of both June 30, 2022 and December 31, 2021.

XML

LEASES

6 Months Ended

Jun. 30, 2022

Leases [Abstract]

LEASES

LEASESThe Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from June 30, 2022. In addition, the Company has historically not been exercising purchase options under the equipment leases as it

does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

On June 22, 2022, the Company signed a ten-year real estate sublease for approximately 40,000 square feet of office space, which will serve as the Company's corporate headquarters and a laboratory facility. The sublease will not commence until the sublandlord substantially completes its work per the sublease agreement, which will most likely occur in the third quarter of 2022. This new sublease will replace the current lease for the Company's corporate headquarters, however the Company anticipates that it will continue to lease the laboratory space in the previous corporate headquarters. The Company will recognize a right of use asset and a lease liability at the commencement date based on ASC 842, Lease Accounting. As of June 30, 2022 the Company did not record a right of use asset or lease liability on the balance sheet in connection with this lease.

The Company has not identified any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the condensed consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2022: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%.

In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At June 30, 2022 and December 31, 2021, the Company had finance lease liabilities of $2,387 and $2,470, respectively, which were recorded under "Lease liabilities" (current and non-current) on the condensed consolidated balance sheets.

Right of use assets and lease liabilities at June 30, 2022 and December 31, 2021 are summarized as follows:

Right of use assets	June 30, 2022		December 31, 2021
Operating leases	$	10,718	$	6,929
Finance leases	2,255		2,359
Total	$	12,973	$	9,288

Lease liabilities - current	June 30, 2022		December 31, 2021
Operating leases	$	2,997	$	2,194
Finance leases	171		167
Total	$	3,168	$	2,361

Lease liabilities - non-current	June 30, 2022		December 31, 2021
Operating leases	$	7,725	$	4,811
Finance leases	2,216		2,303
Total	$	9,941	$	7,114

For the three and six months ended June 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Lease Cost
Operating lease cost	$	811		$	770		$	1,592		$	1,486
Finance Lease cost
Amortization of ROU asset	52			53			104			105
Interest on lease liabilities	30			33			61			66
Total finance lease	82			86			165			171
Total lease cost	$	893		$	856		$	1,757		$	1,657
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	807		$	749		$	1,608		$	1,488
Operating cash flows from finance leases	30			33			61			66
Financing cash flows from finance leases	42			39			83			78
	$	879		$	821		$	1,752		$	1,632
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$	4,615		$	1,376		$	5,277		$	2,412
Weighted-average remaining lease term - operating leases	4.10 years			4.43 years			4.10 years			4.43 years
Weighted-average remaining lease term - finance leases	10.91 years			11.75 years			10.91 years			11.75 years
Weighted-average discount rate - operating leases	3.2		%	3.9		%	3.2		%	3.9		%
Weighted-average discount rate - finance leases	5.1		%	5.1		%	5.1		%	5.1		%

Rent expense charged to operations under operating lease agreements for the three and six months ended June 30, 2022 aggregated to approximately $811 and $1,592, respectively, and $770 and $1,486 for the three and six months ended June 30, 2021, respectively.

LEASES

LEASESThe Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from June 30, 2022. In addition, the Company has historically not been exercising purchase options under the equipment leases as it

does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions.

On June 22, 2022, the Company signed a ten-year real estate sublease for approximately 40,000 square feet of office space, which will serve as the Company's corporate headquarters and a laboratory facility. The sublease will not commence until the sublandlord substantially completes its work per the sublease agreement, which will most likely occur in the third quarter of 2022. This new sublease will replace the current lease for the Company's corporate headquarters, however the Company anticipates that it will continue to lease the laboratory space in the previous corporate headquarters. The Company will recognize a right of use asset and a lease liability at the commencement date based on ASC 842, Lease Accounting. As of June 30, 2022 the Company did not record a right of use asset or lease liability on the balance sheet in connection with this lease.

The Company has not identified any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the condensed consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2022: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%.

In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At June 30, 2022 and December 31, 2021, the Company had finance lease liabilities of $2,387 and $2,470, respectively, which were recorded under "Lease liabilities" (current and non-current) on the condensed consolidated balance sheets.

Right of use assets and lease liabilities at June 30, 2022 and December 31, 2021 are summarized as follows:

Right of use assets	June 30, 2022		December 31, 2021
Operating leases	$	10,718	$	6,929
Finance leases	2,255		2,359
Total	$	12,973	$	9,288

Lease liabilities - current	June 30, 2022		December 31, 2021
Operating leases	$	2,997	$	2,194
Finance leases	171		167
Total	$	3,168	$	2,361

Lease liabilities - non-current	June 30, 2022		December 31, 2021
Operating leases	$	7,725	$	4,811
Finance leases	2,216		2,303
Total	$	9,941	$	7,114

For the three and six months ended June 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Lease Cost
Operating lease cost	$	811		$	770		$	1,592		$	1,486
Finance Lease cost
Amortization of ROU asset	52			53			104			105
Interest on lease liabilities	30			33			61			66
Total finance lease	82			86			165			171
Total lease cost	$	893		$	856		$	1,757		$	1,657
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	807		$	749		$	1,608		$	1,488
Operating cash flows from finance leases	30			33			61			66
Financing cash flows from finance leases	42			39			83			78
	$	879		$	821		$	1,752		$	1,632
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$	4,615		$	1,376		$	5,277		$	2,412
Weighted-average remaining lease term - operating leases	4.10 years			4.43 years			4.10 years			4.43 years
Weighted-average remaining lease term - finance leases	10.91 years			11.75 years			10.91 years			11.75 years
Weighted-average discount rate - operating leases	3.2		%	3.9		%	3.2		%	3.9		%
Weighted-average discount rate - finance leases	5.1		%	5.1		%	5.1		%	5.1		%

Rent expense charged to operations under operating lease agreements for the three and six months ended June 30, 2022 aggregated to approximately $811 and $1,592, respectively, and $770 and $1,486 for the three and six months ended June 30, 2021, respectively.

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap (net investment hedge) with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk.

On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the 2018 Credit Agreement. The net interest expense related to the interest rate swap contract was $364 and $877 for the three and six months ended June 30, 2022, and $534 and $1,055 for the three and six months ended June 30, 2021, respectively, and was recorded in the condensed consolidated statements of earnings under "Interest expense, net." In addition, in connection with the Company's entering into the Amended

and Restated Credit Agreement on July 27, 2022 (see Note 8 "Revolving Loan"), the Company also modified its existing interest rate swap under the relief provided for in ASC 848, "Reference Rate Reform".

On May 28, 2019, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $563 and $1,113 for the three and six months ended June 30, 2022, and $563 and $1,119 for the three and six months ended June 30, 2021, respectively, which were recorded in the condensed consolidated statements of earnings under "Interest expense, net."

The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net "Derivative asset" or "Derivative liability" on the condensed consolidated balance sheets.

As of June 30, 2022 and December 31, 2021, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets:

Derivative assets (liabilities)	June 30, 2022		December 31, 2021
Interest rate swap	$	1,048	$	(2,158)
Cross-currency swap	6,228		(500)
Derivative assets (liabilities)	$	7,276	$	(2,658)

On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.

In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting.

If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting.

As of June 30, 2022, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income.

Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and six months ended June 30, 2022 and 2021:

	Location within Statements of Comprehensive Income	Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021		2022		2021
Cash flow hedge (interest rate swap), net of tax	Unrealized gain/(loss) on cash flow hedge, net	$	850	$	351	$	2,423	$	863
Net investment hedge (cross-currency swap), net of tax	Net foreign currency translation adjustment	3,963		(1,024)		5,086		2,173
Total		$	4,813	$	(673)	$	7,509	$	3,036

On June 21, 2022, the Company completed the acquisition of Kappa (as defined in Note 2 "Significant Acquisitions"). In the process of acquiring Kappa, the Company entered into four short-term foreign currency exchange forward contracts with JP Morgan Chase, N.A to manage fluctuations in foreign currency exchange rates related to the acquisition. The Company did not designate these contracts as hedged transactions under the applicable sections of ASC Topic 815, "Derivatives and Hedging". For the six months ended June 30, 2022, the net gains on these forward contracts of $512 were recorded in other income or loss in the condensed consolidated statements of earnings. As of June 30, 2022, the Company did not maintain any open foreign currency exchange forward contracts as all four contracts expired before June 30, 2022.

The following table summarizes the key terms of the four forward exchange contracts:.

Date entered into	Date expired on	Balchem to sell		Balchem to buy
June 15, 2022	June 21, 2022	USD	294,555	NOK	2,924,553
June 15, 2022	June 17, 2022	USD	6,436	EUR	6,180
June 15, 2022	June 21, 2022	USD	16,640	EUR	15,972
June 15, 2022	June 21, 2022	EUR	15,972	NOK	165,210

XML

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Policies)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted the Standard Update in 2021. The adoption of the Standard update did not have a significant impact on the Company's consolidated financial statements and disclosures.

In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on the Company's consolidated financial statements and disclosures.

XML

SIGNIFICANT ACQUISITIONS (Tables)

6 Months Ended

Jun. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed:

Cash and cash equivalents	$	6,365
Accounts receivable	8,036
Inventories	17,701
Property, plant and equipment	9,854
Right of use assets	3,349
Customer relationships	113,545
Developed technology	18,166
Trademarks	6,055
Other assets	2,399
Accounts payable	(3,301)
Bank debt	(30,648)
Lease liabilities	(3,349)
Other liabilities	(4,373)
Deferred income taxes, net	(29,127)
Goodwill	212,591
Total consideration on acquisition date	327,263
Contingent consideration liability	(24,726)
Net gains on foreign currency exchange forward contracts	(512)
Amount paid to shareholders	302,025
Kappa bank debt paid on purchase date	30,648
Total amount paid on acquisition date	$	332,673

Schedule of Unaudited Pro Forma Information

The following preliminary unaudited pro forma information has been prepared as if the acquisition had occurred on January 1, 2021.

	Three Months Ended June 30,				Six Months Ended June 30,
	Net Sales		Net Earnings		Net Sales		Net Earnings
Kappa actual results included in the Company's consolidated income statement from June 21, 2022 through June 30, 2022	$	—	$	—	$	—	$	—
2022 Supplemental pro forma combined financial information	$	247,430	$	30,172	$	489,170	$	58,648
2021 Supplemental pro forma combined financial information	$	213,032	$	26,344	$	410,649	$	50,379

XML

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2022

Stockholders' Equity Note [Abstract]

Schedule of Compensation Cost on Net Earnings

The Company’s results for the three and six months ended June 30, 2022 and 2021 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

	Increase/(Decrease) for the				Increase/(Decrease) for the
	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cost of sales	$	277	$	444	$	676	$	744
Operating expenses	3,535		2,849		6,213		5,170
Net earnings	(2,933)		(2,547)		(5,312)		(4,569)

Schedule of Stock Option Activity

Option activity for the six months ended June 30, 2022 and 2021 is summarized below:

For the six months ended June 30, 2022	Shares (000s)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2021	867	$	88.19	$	69,711
Granted	109	138.07
Exercised	(18)	72.74
Forfeited	(6)	120.36
Canceled	—	—
Outstanding as of June 30, 2022	952	$	93.99	$	34,907	6.4
Exercisable as of June 30, 2022	666	$	81.11	$	32,409	5.4

For the six months ended June 30, 2021	Shares (000s)	Weighted Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2020	858	$	80.58	$	29,735
Granted	129	119.12
Exercised	(58)	65.95
Forfeited	(2)	101.38
Canceled	(1)	74.57
Outstanding as of June 30, 2021	926	$	86.85	$	41,107	6.8
Exercisable as of June 30, 2021	580	$	73.72	$	33,398	5.6

Schedule of Other Information Pertaining to Stock Option Activity

Other information pertaining to option activity during the three and six months ended June 30, 2022 and 2021 is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Weighted-average fair value of options granted	$	—	$	34.42	$	40.26	$	33.11
Total intrinsic value of stock options exercised ($000s)	$	495	$	1,814	$	1,149	$	3,731

Schedule of Non-vested Restricted Stock Activity

Non-vested restricted stock activity for the six months ended June 30, 2022 and 2021 is summarized below:

	Six Months Ended June 30,
	2022			2021
	Shares (000s)	Weighted Average Grant Date Fair Value		Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31	166	$	99.70	159	$	90.71
Granted	34	137.74		37	119.30
Vested	(77)	80.84		(13)	87.33
Forfeited	(3)	116.73		(2)	85.60
Non-vested balance as of June 30	120	$	122.03	181	$	96.89

Schedule of Non-vested Performance Share Activity

Non-vested performance share activity for the six months ended June 30, 2022 and 2021 is summarized below:

	Six Months Ended June 30,
	2022			2021
	Shares (000s)	Weighted Average Grant Date Fair Value		Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31	69	$	110.72	71	$	91.99
Granted	39	114.22		36	108.74
Vested	(35)	53.17		(24)	70.64
Forfeited	(3)	84.09		(11)	74.57
Non-vested balance as of June 30	70	$	127.69	72	$	110.22

XML

INVENTORIES (Tables)

6 Months Ended

Jun. 30, 2022

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories at June 30, 2022 and December 31, 2021 consisted of the following:

	June 30, 2022		December 31, 2021
Raw materials	$	43,342	$	28,639
Work in progress	20,249		10,563
Finished goods	77,249		51,856
Total inventories	$	140,840	$	91,058

XML

PROPERTY, PLANT AND EQUIPMENT (Tables)

6 Months Ended

Jun. 30, 2022

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment at June 30, 2022 and December 31, 2021 are summarized as follows:

	June 30, 2022		December 31, 2021
Land	$	11,273	$	11,692
Building	91,140		89,602
Equipment	263,929		253,995
Construction in progress	65,906		52,930
	432,248		408,219
Less: accumulated depreciation	180,103		170,702
Property, plant and equipment, net	$	252,145	$	237,517

XML

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Identifiable Intangible Assets

Identifiable intangible assets with finite lives at June 30, 2022 and December 31, 2021 are summarized as follows:

	Amortization Period (in years)	Gross Carrying Amount at 6/30/2022		Accumulated Amortization at 6/30/2022		Gross Carrying Amount at 12/31/2021		Accumulated Amortization at 12/31/2021
Customer relationships & lists	10-20	$	350,523	$	180,638	$	240,059	$	173,489
Trademarks & trade names	2-17	48,724		30,968		43,116		28,985
Developed technology	5-12	38,252		14,993		20,234		14,607
Other	2-18	24,687		16,785		23,921		15,584
		$	462,186	$	243,384	$	327,330	$	232,665

XML

NET EARNINGS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Reconciliation of the Net Earnings and Shares Used in Calculating Basic and Diluted Net Earnings Per Share

The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net Earnings - Basic and Diluted	$	29,782	$	22,731	$	58,712	$	46,142
Shares (000s)
Weighted Average Common Shares - Basic	31,999		32,232		32,020		32,243
Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares	315		419		375		410
Weighted Average Common Shares - Diluted	32,314		32,651		32,395		32,653
Net Earnings Per Share - Basic	$	0.93	$	0.71	$	1.83	$	1.43
Net Earnings Per Share - Diluted	$	0.92	$	0.70	$	1.81	$	1.41

XML

SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The segment information is summarized as follows:

Business Segment Assets	June 30, 2022		December 31, 2021
Human Nutrition & Health	$	1,146,749	$	727,131
Animal Nutrition & Health	171,605		158,971
Specialty Products	179,573		184,628
Other and Unallocated (1)	108,747		128,595
Total	$	1,606,674	$	1,199,325

Business Segment Net Sales	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	131,628	$	111,471	$	254,073	$	215,987
Animal Nutrition & Health	62,600		54,481		131,942		105,629
Specialty Products	36,647		34,022		69,981		62,030
Other and Unallocated (2)	5,818		2,391		9,564		4,375
Total	$	236,693	$	202,365	$	465,560	$	388,021

Business Segment Earnings Before Income Taxes	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	23,705	$	19,021	$	44,008	$	38,711
Animal Nutrition & Health	7,586		3,561		18,907		8,617
Specialty Products	9,919		9,729		17,680		16,918
Other and Unallocated (2)	(1,290)		(1,718)		(2,339)		(3,078)
Interest and other expense	(662)		(574)		(1,368)		(1,166)
Total	$	39,258	$	30,019	$	76,888	$	60,002

Depreciation/Amortization	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Human Nutrition & Health	$	7,392	$	7,441	$	14,747	$	15,014
Animal Nutrition & Health	1,668		1,816		3,329		3,580
Specialty Products	1,899		2,085		3,831		4,354
Other and Unallocated (2)	974		757		1,954		1,515
Total	$	11,933	$	12,099	$	23,861	$	24,463

Capital Expenditures	Six Months Ended June 30,
	2022		2021
Human Nutrition & Health	$	11,006	$	8,883
Animal Nutrition & Health	6,559		2,729
Specialty Products	2,206		1,448
Other and Unallocated (2)	338		66
Total	$	20,109	$	13,126

(1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation.

(2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $872 and $1,176 for the three and six months ended June 30, 2022, respectively, and $466 and $700 for the three and six months ended June 30, 2021, respectively, and (ii) Unallocated amortization expense of $811 and $1,620 for the three and six months ended June 30, 2022, respectively, and $674 and $1,349 for the three and six months ended June 30, 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that were included in interest expense in the Company's condensed consolidated statements of earnings.

XML

REVENUE (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenues

The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues.

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product Sales	$	225,260	$	193,122	$	443,313	$	369,110
Co-manufacturing	9,819		6,878		18,126		14,156
Consignment	989		1,380		2,580		2,431
Product Sales Revenue	236,068		201,380		464,019		385,697
Royalty Revenue	625		985		1,541		2,324
Total Revenue	$	236,693	$	202,365	$	465,560	$	388,021

The following table presents revenues disaggregated by geography, based on the shipping addresses of customers:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	169,076	$	147,188	$	343,567	$	285,039
Foreign Countries	67,617		55,177		121,993		102,982
Total Revenue	$	236,693	$	202,365	$	465,560	$	388,021

XML

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)

6 Months Ended

Jun. 30, 2022

Supplemental Cash Flow Information [Abstract]

Schedule of Supplemental Cash Flow Information

Cash paid during the six months ended June 30, 2022 and 2021 for income taxes and interest is as follows:

	Six Months Ended June 30,
	2022		2021
Income taxes	$	15,562	$	12,493
Interest	$	1,960	$	2,452

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)

6 Months Ended

Jun. 30, 2022

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive (loss)/income were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net foreign currency translation adjustment	$	(6,951)	$	1,524	$	(9,793)	$	(4,619)
Net change of cash flow hedge (see Note 20 for further information)
Unrealized gain on cash flow hedge	1,122		456		3,206		1,133
Tax	(272)		(105)		(783)		(270)
Net of tax	850		351		2,423		863
Net change in postretirement benefit plan (see Note 15 for further information)
Amortization of prior service cost	2		19		4		37
Amortization of gain	—		(7)		—		(12)
Gain arising during the period and prior service credit	(9)		—		(41)		(4)
Total before tax	(7)		12		(37)		21
Tax	(27)		(4)		(24)		(6)
Net of tax and adjustment	(34)		8		(61)		15
Total other comprehensive (loss)/income	$	(6,135)	$	1,883	$	(7,431)	$	(3,741)

Schedule of Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive (loss)/income at June 30, 2022 and December 31, 2021 consisted of the following:

	Foreign currency translation adjustment		Cash flow hedge		Postretirement benefit plan		Total
Balance December 31, 2021	$	(3,602)	$	(1,631)	$	240	$	(4,993)
Other comprehensive (loss)/income	(9,793)		2,423		(61)		(7,431)
Balance June 30, 2022	$	(13,395)	$	792	$	179	$	(12,424)

XML

EMPLOYEE BENEFIT PLANS (Tables)

6 Months Ended

Jun. 30, 2022

Retirement Benefits [Abstract]

Schedule of Net Periodic Benefit Cost

Net periodic benefit costs for such retirement medical plans were as follows:

	Six Months Ended June 30,
	2022		2021
Service cost	$	39	$	43
Interest cost	13		12
Amortization of prior service cost	4		37
Amortization of gain	—		(12)
Net periodic benefit cost	$	56	$	80

Net periodic benefit costs for such benefit pensions plans were as follows:

	Six Months Ended June 30,
	2022		2021
Service cost with interest to end of year	$	29	$	35
Interest cost	12		7
Expected return on plan assets	(25)		(18)
Amortization of gain	—		2
Total net periodic benefit cost	$	16	$	26

XML

COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases

Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at June 30, 2022 are as follows:

Year
July 1, 2022 to December 31, 2022	$	1,896
2023	3,551
2024	3,754
2025	2,824
2026	2,451
2027	2,093
Thereafter	6,225
Total minimum lease payments	$	22,794

XML

LEASES (Tables)

6 Months Ended

Jun. 30, 2022

Leases [Abstract]

Schedule of Right of Use Asset and Lease Liabilities

Right of use assets and lease liabilities at June 30, 2022 and December 31, 2021 are summarized as follows:

Right of use assets	June 30, 2022		December 31, 2021
Operating leases	$	10,718	$	6,929
Finance leases	2,255		2,359
Total	$	12,973	$	9,288

Lease liabilities - current	June 30, 2022		December 31, 2021
Operating leases	$	2,997	$	2,194
Finance leases	171		167
Total	$	3,168	$	2,361

Lease liabilities - non-current	June 30, 2022		December 31, 2021
Operating leases	$	7,725	$	4,811
Finance leases	2,216		2,303
Total	$	9,941	$	7,114

Schedule of Lease Cost

For the three and six months ended June 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions:

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Lease Cost
Operating lease cost	$	811		$	770		$	1,592		$	1,486
Finance Lease cost
Amortization of ROU asset	52			53			104			105
Interest on lease liabilities	30			33			61			66
Total finance lease	82			86			165			171
Total lease cost	$	893		$	856		$	1,757		$	1,657
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	807		$	749		$	1,608		$	1,488
Operating cash flows from finance leases	30			33			61			66
Financing cash flows from finance leases	42			39			83			78
	$	879		$	821		$	1,752		$	1,632
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$	4,615		$	1,376		$	5,277		$	2,412
Weighted-average remaining lease term - operating leases	4.10 years			4.43 years			4.10 years			4.43 years
Weighted-average remaining lease term - finance leases	10.91 years			11.75 years			10.91 years			11.75 years
Weighted-average discount rate - operating leases	3.2		%	3.9		%	3.2		%	3.9		%
Weighted-average discount rate - finance leases	5.1		%	5.1		%	5.1		%	5.1		%

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Fair Value of Derivative Instruments

As of June 30, 2022 and December 31, 2021, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets:

Derivative assets (liabilities)	June 30, 2022		December 31, 2021
Interest rate swap	$	1,048	$	(2,158)
Cross-currency swap	6,228		(500)
Derivative assets (liabilities)	$	7,276	$	(2,658)

Schedule of Gains (Losses) on Hedging Instruments

Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and six months ended June 30, 2022 and 2021:

	Location within Statements of Comprehensive Income	Three Months Ended June 30,				Six Months Ended June 30,
		2022		2021		2022		2021
Cash flow hedge (interest rate swap), net of tax	Unrealized gain/(loss) on cash flow hedge, net	$	850	$	351	$	2,423	$	863
Net investment hedge (cross-currency swap), net of tax	Net foreign currency translation adjustment	3,963		(1,024)		5,086		2,173
Total		$	4,813	$	(673)	$	7,509	$	3,036

Summary Of Key Terms of Forward Exchange Contracts

The following table summarizes the key terms of the four forward exchange contracts:.

Date entered into	Date expired on	Balchem to sell		Balchem to buy
June 15, 2022	June 21, 2022	USD	294,555	NOK	2,924,553
June 15, 2022	June 17, 2022	USD	6,436	EUR	6,180
June 15, 2022	June 21, 2022	USD	16,640	EUR	15,972
June 15, 2022	June 21, 2022	EUR	15,972	NOK	165,210

XML

SIGNIFICANT ACQUISITIONS - Narrative (Details) kr in Thousands			3 Months Ended		6 Months Ended
	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 NOK (kr)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Cash paid for acquisition, net of cash acquired					$ 295,660,000	$ 0
Contingent consideration liability			$ 24,793,000		24,793,000			$ 0
Goodwill			731,772,000		731,772,000			$ 523,949,000
Kechu BidCo AS
Business Acquisition [Line Items]
Business combination acquiring | kr		kr 3,301,341
Total amount paid on acquisition date	$ 332,673,000
Kappa bank debt paid on purchase date	30,648,000	303,672
Cash acquired from acquisition	6,365,000	63,064
Cash paid for acquisition, net of cash acquired	326,820,000	kr 3,238,277
Contingent consideration liability			24,793,000		24,793,000		kr 245,000
Goodwill	$ 212,591,000
Transaction and integration related costs			451,000	$ 0	451,000	0
Pre forma net earnings			30,172,000	$ 26,344,000	58,648,000	$ 50,379,000
Acquisition related costs			$ 643,000		$ 722,000
Kechu BidCo AS | Customer relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired	15 years	15 years
Kechu BidCo AS | Corporate trademark
Business Acquisition [Line Items]
Useful life of intangible assets acquired	2 years	2 years
Kechu BidCo AS | Product trademarks
Business Acquisition [Line Items]
Useful life of intangible assets acquired	10 years	10 years
Kechu BidCo AS | Developed technology
Business Acquisition [Line Items]
Useful life of intangible assets acquired	12 years	12 years
Kechu BidCo AS | Former Shareholder
Business Acquisition [Line Items]
Total amount paid on acquisition date | kr		kr 2,997,669
Cash paid for acquisition, net of cash acquired	$ 302,537,000

XML

SIGNIFICANT ACQUISITIONS - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) kr in Thousands, $ in Thousands	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill			$ 731,772	$ 523,949
Kechu BidCo AS
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and cash equivalents	$ 6,365
Accounts receivable	8,036
Inventories	17,701
Property, plant and equipment	9,854
Right of use assets	3,349
Other assets	2,399
Accounts payable	(3,301)
Bank debt	(30,648)
Lease liabilities	(3,349)
Other liabilities	(4,373)
Deferred income taxes, net	(29,127)
Goodwill	212,591
Total consideration on acquisition date	327,263
Contingent consideration liability	(24,726)
Net gains on foreign currency exchange forward contracts	(512)
Amount paid to shareholders	302,025
Kappa bank debt paid on purchase date	30,648	kr 303,672
Total amount paid on acquisition date	332,673
Kechu BidCo AS | Customer relationships
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets	113,545
Kechu BidCo AS | Developed technology
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets	18,166
Kechu BidCo AS | Trademarks
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets	$ 6,055

XML

SIGNIFICANT ACQUISITIONS - Unaudited Pro Forma Information (Details) - Kechu BidCo AS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition, Pro Forma Information [Abstract]
Kappa actual results, net sales	$ 0		$ 0
Kappa actual results, net earnings	0		0
Pre forma net sales	247,430	$ 213,032	489,170	$ 410,649
Pre forma net earnings	$ 30,172	$ 26,344	$ 58,648	$ 50,379

XML

STOCKHOLDERS' EQUITY - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Net earnings	$ (2,933)	$ (2,547)	$ (5,312)	$ (4,569)
Expiration period of options granted			10 years
Shares available for future awards (in shares)	534,120		534,120
Stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			4 years
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 277	444	$ 676	744
Operating expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 3,535	$ 2,849	$ 6,213	$ 5,170

XML

STOCKHOLDERS' EQUITY - Stock Options (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)			867	858
Granted (in shares)			109	129
Exercised (in shares)			(18)	(58)
Forfeited (in shares)			(6)	(2)
Canceled (in shares)			0	(1)
Outstanding at end of period (in shares)	952	926	952	926
Exercisable at end of period (in shares)	666	580	666	580
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period (in dollars per share)			$ 88.19	$ 80.58
Granted (in dollars per share)			138.07	119.12
Exercised (in dollars per share)			72.74	65.95
Forfeited (in dollars per share)			120.36	101.38
Canceled (in dollars per share)			0	74.57
Outstanding at end of period (in dollars per share)	$ 93.99	$ 86.85	93.99	86.85
Exercisable at end of period (in dollars per share)	$ 81.11	$ 73.72	$ 81.11	$ 73.72
Aggregate intrinsic value, outstanding, beginning of period			$ 69,711	$ 29,735
Aggregate intrinsic value, outstanding, end of period	$ 34,907	$ 41,107	34,907	41,107
Aggregate intrinsic value, exercisable, end of period	$ 32,409	$ 33,398	$ 32,409	$ 33,398
Weighted average remaining contractual term, outstanding			6 years 4 months 24 days	6 years 9 months 18 days
Weighted average remaining contractual term, exercisable			5 years 4 months 24 days	5 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield rate			0.50%	0.50%
Expected volatility rate			31.00%	33.00%
Risk-free interest rate			2.00%	0.50%
Expected term			4 years 10 months 24 days	4 years 10 months 24 days
Weighted-average fair value of options granted (in dollars per share)	$ 0	$ 34.42	$ 40.26	$ 33.11
Total intrinsic value of stock options exercised	$ 495	$ 1,814	$ 1,149	$ 3,731

XML

STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Unrecognized compensation cost	$ 19,988	$ 19,796
Period for unrecognized compensation cost to be recognized over	1 year 8 months 12 days
Estimated share-based compensation expense	$ 13,000
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	166	159
Granted (in shares)	34	37
Vested (in shares)	(77)	(13)
Forfeited (in shares)	(3)	(2)
Non-vested balance as of end of period (in shares)	120	181
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 99.70	$ 90.71
Granted (in dollars per share)	137.74	119.30
Vested (in dollars per share)	80.84	87.33
Forfeited (in dollars per share)	116.73	85.60
Non-vested balance as of end of period (in dollars per share)	$ 122.03	$ 96.89
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	69	71
Granted (in shares)	39	36
Vested (in shares)	(35)	(24)
Forfeited (in shares)	(3)	(11)
Non-vested balance as of end of period (in shares)	70	72
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 110.72	$ 91.99
Granted (in dollars per share)	114.22	108.74
Vested (in dollars per share)	53.17	70.64
Forfeited (in dollars per share)	84.09	74.57
Non-vested balance as of end of period (in dollars per share)	$ 127.69	$ 110.22
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	1.80%	0.20%
Dividend yield rate	0.50%	0.60%
Expected volatility rate	32.00%	33.00%
Initial TSR	(15.70%)	11.70%
Cliff vest	100.00%

XML

STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Number of shares authorized to be repurchased (in shares)		3,763,038
Aggregate number of shares repurchased since inception (in shares)		3,068,905
Reclassification [Line Items]
Number of shares acquired under stock repurchase plan and subsequently reissued (in shares)		250,661	86,124
Treasury stock acquired, average cost (in dollars per share)		$ 140.42	$ 125.81
Revision of Prior Period, Reclassification, Adjustment
Reclassification [Line Items]
Repurchases of common stock	$ 2,210		$ 8,472	$ 7,873

XML

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 43,342	$ 28,639
Work in progress	20,249	10,563
Finished goods	77,249	51,856
Total inventories	$ 140,840	$ 91,058

XML

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 432,248	$ 408,219
Less: accumulated depreciation	180,103	170,702
Property, plant and equipment, net	252,145	237,517
Land
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	11,273	11,692
Building
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	91,140	89,602
Equipment
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	263,929	253,995
Construction in progress
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 65,906	$ 52,930

XML

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 731,772,000		$ 731,772,000		$ 523,949,000
Amortization of identifiable intangible assets	5,850,000	$ 6,229,000	11,761,000	$ 12,713,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2021	14,485,000		14,485,000
2022	27,923,000		27,923,000
2023	19,659,000		19,659,000
2024	16,117,000		16,117,000
2025	15,710,000		15,710,000
2026	14,949,000		14,949,000
Identifiable intangible assets with indefinite useful lives	$ 0		$ 0		$ 0

XML

INTANGIBLE ASSETS - Schedule of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 462,186	$ 327,330
Accumulated amortization	243,384	232,665
Customer relationships & lists
Identifiable intangible assets [Abstract]
Gross carrying amount	350,523	240,059
Accumulated amortization	$ 180,638	173,489
Customer relationships & lists | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	10 years
Customer relationships & lists | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	20 years
Trademarks & trade names
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 48,724	43,116
Accumulated amortization	$ 30,968	28,985
Trademarks & trade names | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	2 years
Trademarks & trade names | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	17 years
Developed technology
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 38,252	20,234
Accumulated amortization	$ 14,993	14,607
Developed technology | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	5 years
Developed technology | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	12 years
Other
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 24,687	23,921
Accumulated amortization	$ 16,785	$ 15,584
Other | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	2 years
Other | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	18 years

XML

EQUITY-METHOD INVESTMENT (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) vote	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Equity Method Investment, Summarized Financial Information [Abstract]
Percentage of operating expenses to be absorbed			66.66%
Percentage of production offtake			66.66%
St. Gabriel CC Company, LLC
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	66.66%		66.66%
Number of votes | vote			2
Loss relating to joint venture's expenses	$ 140	$ 130	$ 280	$ 274
Capital contributions	75		133
Net return of capital		$ 28		$ 15
Carrying value of joint venture	$ 4,352		$ 4,352		$ 4,499
St. Gabriel CC Company, LLC | Eastman Chemical Company
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	33.34%		33.34%
Number of votes | vote			2

XML

REVOLVING LOAN (Details) - USD ($)			3 Months Ended		6 Months Ended
	Jul. 27, 2022	Jun. 27, 2018	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Repayments of outstanding balance					$ 40,000,000	$ 45,000,000
Proceeds from revolving loan					365,000,000	5,000,000
Outstanding balance			$ 433,569,000		433,569,000		$ 108,569,000
Capitalized costs net of accumulated amortization			280,000		280,000		421,000
Amortization expense pertaining to capitalized costs			$ 70,000	$ 70,000	$ 141,000	$ 141,000
Credit agreement
Debt Instrument [Line Items]
Interest rate			2.538%		2.538%
Commitment fee percentage					0.15%
Unused portion of revolving loan			$ 66,431,000		$ 66,431,000
Credit agreement | Minimum
Debt Instrument [Line Items]
Commitment fee percentage					0.15%
Credit agreement | Maximum
Debt Instrument [Line Items]
Commitment fee percentage					0.275%
Credit agreement | Term loan
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 350,000,000
Repayments of outstanding balance		210,750,000
Credit agreement | Revolving
Debt Instrument [Line Items]
Maximum borrowing capacity		100,000,000
Loans | Revolving
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 500,000,000
Outstanding balance			433,569,000		$ 433,569,000		$ 108,569,000
Installment payments required					$ 0
Loans | Revolving | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 550,000,000
Repayments of outstanding balance	$ 433,569,000
Revolving loan | Revolving
Debt Instrument [Line Items]
Proceeds from revolving loan			$ 345,000,000

XML

NET EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Earnings - Basic and Diluted	$ 29,782	$ 28,930	$ 22,731	$ 23,411	$ 58,712	$ 46,142
Weighted average common shares - basic (in shares)	31,999,000		32,232,000		32,020,000	32,243,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)	315,000		419,000		375,000	410,000
Weighted average common shares - diluted (in shares)	32,314,000		32,651,000		32,395,000	32,653,000
Net earnings per share - basic (in dollars per share)	$ 0.93		$ 0.71		$ 1.83	$ 1.43
Net earnings per share - diluted (in dollars per share)	$ 0.92		$ 0.70		$ 1.81	$ 1.41
Anti-dilutive shares (in shares)	294,568		153,868		237,453	304,324

XML

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	24.10%	24.30%	23.60%	23.10%
Unrecognized tax benefits	$ 5,902		$ 5,902		$ 5,881
Accrued interest and penalties related to unrecognized tax benefits	$ 2,214		$ 2,214		$ 2,106

XML

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
	Jun. 30, 2022 filling_facility segment
Segment Reporting [Abstract]
Number of business segments | segment	3
Number of filling facilities | filling_facility	5

XML

SEGMENT INFORMATION - Business Segment Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Segment information [Abstract]
Assets	$ 1,606,674	$ 1,199,325
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Assets	1,146,749	727,131
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Assets	171,605	158,971
Operating segments | Specialty Products
Segment information [Abstract]
Assets	179,573	184,628
Other and unallocated
Segment information [Abstract]
Assets	$ 108,747	$ 128,595

XML

SEGMENT INFORMATION - Business Segment Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment information [Abstract]
Net sales	$ 236,693	$ 202,365	$ 465,560	$ 388,021
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Net sales	131,628	111,471	254,073	215,987
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Net sales	62,600	54,481	131,942	105,629
Operating segments | Specialty Products
Segment information [Abstract]
Net sales	36,647	34,022	69,981	62,030
Other and unallocated
Segment information [Abstract]
Net sales	$ 5,818	$ 2,391	$ 9,564	$ 4,375

XML

SEGMENT INFORMATION - Business Segment Earnings Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment information [Abstract]
Earnings before income taxes	$ 39,258	$ 30,019	$ 76,888	$ 60,002
Interest and other (expense)	(662)	(574)	(1,368)	(1,166)
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Earnings before income taxes	23,705	19,021	44,008	38,711
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Earnings before income taxes	7,586	3,561	18,907	8,617
Operating segments | Specialty Products
Segment information [Abstract]
Earnings before income taxes	9,919	9,729	17,680	16,918
Other and unallocated
Segment information [Abstract]
Earnings before income taxes	(1,290)	(1,718)	(2,339)	(3,078)
Interest and other expense
Segment information [Abstract]
Interest and other (expense)	$ (662)	$ (574)	$ (1,368)	$ (1,166)

XML

SEGMENT INFORMATION - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment information [Abstract]
Depreciation and amortization	$ 11,933	$ 12,099	$ 23,861	$ 24,463
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Depreciation and amortization	7,392	7,441	14,747	15,014
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Depreciation and amortization	1,668	1,816	3,329	3,580
Operating segments | Specialty Products
Segment information [Abstract]
Depreciation and amortization	1,899	2,085	3,831	4,354
Other and unallocated
Segment information [Abstract]
Depreciation and amortization	$ 974	$ 757	$ 1,954	$ 1,515

XML

SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment information [Abstract]
Capital expenditures			$ 20,109	$ 13,126
Amortization of identifiable intangible assets	$ 5,850	$ 6,229	11,761	12,713
Other and unallocated
Segment information [Abstract]
Capital expenditures			338	66
Transaction and integration related costs	872	466	1,176	700
Amortization of identifiable intangible assets	$ 811	$ 674	1,620	1,349
Human Nutrition & Health | Operating segments
Segment information [Abstract]
Capital expenditures			11,006	8,883
Animal Nutrition & Health | Operating segments
Segment information [Abstract]
Capital expenditures			6,559	2,729
Specialty Products | Operating segments
Segment information [Abstract]
Capital expenditures			$ 2,206	$ 1,448

XML

REVENUE - Schedule of Disaggregation of Revenues (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) revenue_substream	Jun. 30, 2021 USD ($)
Revenue [Abstract]
Net sales	$ 236,693	$ 202,365	$ 465,560	$ 388,021
United States
Revenue [Abstract]
Net sales	169,076	147,188	343,567	285,039
Foreign Countries
Revenue [Abstract]
Net sales	67,617	55,177	121,993	102,982
Product Sales
Revenue [Abstract]
Net sales	225,260	193,122	443,313	369,110
Co-manufacturing
Revenue [Abstract]
Net sales	9,819	6,878	18,126	14,156
Consignment
Revenue [Abstract]
Net sales	989	1,380	2,580	2,431
Product Sales Revenue
Revenue [Abstract]
Net sales	236,068	201,380	$ 464,019	385,697
Number of sub-streams of revenue | revenue_substream			3
Royalty Revenue
Revenue [Abstract]
Net sales	$ 625	$ 985	$ 1,541	$ 2,324

XML

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Supplemental Cash Flow Information [Abstract]
Income taxes	$ 15,562	$ 12,493
Interest	$ 1,960	$ 2,452

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Changes in accumulated other comprehensive income (loss) [Abstract]
Net foreign currency translation adjustment	$ (6,951)		$ 1,524		$ (9,793)	$ (4,619)
Unrealized gain on cash flow hedge	1,122		456		3,206	1,133
Tax	(272)		(105)		(783)	(270)
Net of tax	850		351		2,423	863
Net change in postretirement benefit plan (see Note 15 for further information)
Amortization of prior service cost	2		19		4	37
Amortization of gain	0		(7)		0	(12)
Gain arising during the period and prior service credit	(9)		0		(41)	(4)
Total before tax	(7)		12		(37)	21
Tax	(27)		(4)		(24)	(6)
Net of tax and adjustment	(34)		8		(61)	15
Other comprehensive income (loss)	(6,135)	$ (1,296)	1,883	$ (5,624)	(7,431)	(3,741)
Cross-currency swap
Net change in postretirement benefit plan (see Note 15 for further information)
Tax expense (benefit) on net investment hedge	1,309		(336)		1,642	690
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	3,963		(1,024)		5,086	2,173
Tax expense (benefit) on net investment hedge	$ 1,309		$ (336)		$ 1,642	$ 690

XML

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 873,682	$ 877,015	$ 849,492	$ 828,233	$ 877,015	$ 828,233
Other comprehensive (loss)/income	(6,135)	(1,296)	1,883	(5,624)	(7,431)	(3,741)
Ending balance	901,370	873,682	869,642	849,492	901,370	869,642
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		(3,602)			(3,602)
Other comprehensive (loss)/income					(9,793)
Ending balance	(13,395)				(13,395)
Cash flow hedge
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		(1,631)			(1,631)
Other comprehensive (loss)/income					2,423
Ending balance	792				792
Postretirement benefit plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance		240			240
Other comprehensive (loss)/income					(61)
Ending balance	179				179
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(6,289)	(4,993)	(1,451)	4,173	(4,993)	4,173
Other comprehensive (loss)/income	(6,135)	(1,296)	1,883	(5,624)
Ending balance	$ (12,424)	$ (6,289)	$ 432	$ (1,451)	$ (12,424)	$ 432

XML

EMPLOYEE BENEFIT PLANS (Details) $ in Thousands			6 Months Ended
	Jun. 21, 2022 plan	Jan. 01, 2021 plan	Jun. 30, 2022 USD ($) plan	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan | plan		1	2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Deferred compensation liability			$ 8,252		$ 6,270
Noncurrent deferred compensation liability			8,220		6,251
Current deferred compensation liability			32		19
Related rabbi trust assets			$ 8,255		6,267
Postretirement Medical Plans
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit plans | plan			2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost			$ 39	$ 43
Interest cost			13	12
Amortization of prior service cost			4	37
Amortization of gain			0	(12)
Net periodic benefit cost			56	80
Benefit obligation			1,221		1,293
Historical cash payments for retirement medical plan claims per year (less than)			200
Defined Benefit Pension Plans | Chemogas Defined Pension Plan
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost			29	35
Interest cost			12	7
Expected return on plan assets			(25)	(18)
Amortization of gain			0	2
Net periodic benefit cost			16	$ 26
Benefit obligation			$ 641		$ 684
Kappa
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan | plan	1

XML

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
July 1, 2022 to December 31, 2022	$ 1,896
2023	3,551
2024	3,754
2025	2,824
2026	2,451
2027	2,093
Thereafter	6,225
Total minimum lease payments	$ 22,794

XML

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) financial_instrument	Dec. 31, 2021 USD ($)
Fair value of financial instruments [Abstract]
Number of financial instruments held for trading purposes | financial_instrument	0
Related rabbi trust assets	$ 8,255	$ 6,267
Derivative assets (liabilities)	7,276	(2,658)
Cross-currency swap
Fair value of financial instruments [Abstract]
Derivative assets (liabilities)	6,228	(500)
Interest rate swap
Fair value of financial instruments [Abstract]
Derivative assets (liabilities)	1,048	(2,158)
Money market funds | Level 1
Fair value of financial instruments [Abstract]
Cash and cash equivalents	$ 927	$ 933

XML

RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Related party transactions [Abstract]
Finished goods received from related party recorded in cost of goods sold	$ 8,233	$ 5,210	$ 14,722	$ 9,601
Receivable from related party	8,224		8,224		$ 10,504
Payables to related parties	5,829		5,829		7,552
Related party receivable related to non-contractual monies	0		0		164
Related party payable related to non-contractual monies	296		296		$ 296
Services provided
Related party transactions [Abstract]
Revenue from related party	1,022	920	1,997	1,747
Raw materials sold
Related party transactions [Abstract]
Revenue from related party	$ 10,910	$ 6,580	$ 20,221	$ 12,042

XML

LEASES - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) tranche	Jun. 30, 2021 USD ($)	Jun. 22, 2022 ft²	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Reasonably certain criterion renewal period	2 years		2 years
Number of tranches | tranche			4
Finance lease liability	$ 2,387		$ 2,387			$ 2,470
Rent expense charged to operations under lease agreements	$ 811	$ 770	$ 1,592	$ 1,486
Corporate Headquarters And Laboratory Facility
Lessee, Lease, Description [Line Items]
Term of contract for operating leases					10 years
Office space | ft²					40,000
Years 1 and 2
Lessee, Lease, Description [Line Items]
Discount rate	1.45%		1.45%
Years 1 and 2 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	1 year		1 year
Years 1 and 2 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	2 years		2 years
Years 3 and 4
Lessee, Lease, Description [Line Items]
Discount rate	2.04%		2.04%
Years 3 and 4 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	3 years		3 years
Years 3 and 4 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	4 years		4 years
Years 5 and 9
Lessee, Lease, Description [Line Items]
Discount rate	2.38%		2.38%
Years 5 and 9 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	5 years		5 years
Years 5 and 9 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	9 years		9 years
Years more than 10
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	10 years		10 years
Discount rate	3.10%		3.10%

XML

LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Right of use assets
Right of use assets - operating leases	$ 10,718	$ 6,929
Finance Leases - ROU	2,255	2,359
Total right-of-use assets	12,973	9,288
Operating leases liabilities - current	2,997	2,194
Finance lease liabilities - current	171	167
Total lease liabilities, current	3,168	2,361
Operating leases liabilities - non-current	7,725	4,811
Finance lease liabilities - non-current	2,216	2,303
Total lease liabilities, non-current	$ 9,941	$ 7,114

XML

LEASES - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Lease Cost
Operating lease cost	$ 811	$ 770	$ 1,592	$ 1,486
Amortization of ROU asset	52	53	104	105
Interest on lease liabilities	30	33	61	66
Total finance lease	82	86	165	171
Total lease cost	893	856	1,757	1,657
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	807	749	1,608	1,488
Operating cash flows from finance leases	30	33	61	66
Financing cash flows from finance leases	42	39	83	78
Cash flows from operating and finance leases	879	821	1,752	1,632
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$ 4,615	$ 1,376	$ 5,277	$ 2,412
Weighted-average remaining lease term - operating leases	4 years 1 month 6 days	4 years 5 months 4 days	4 years 1 month 6 days	4 years 5 months 4 days
Weighted-average remaining lease term - finance leases	10 years 10 months 28 days	11 years 9 months	10 years 10 months 28 days	11 years 9 months
Weighted-average discount rate - operating leases	3.20%	3.90%	3.20%	3.90%
Weighted-average discount rate - finance leases	5.10%	5.10%	5.10%	5.10%

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 21, 2022 derivative	May 28, 2019 USD ($)
Interest rate swap | Interest expense
Derivative [Line Items]
Net interest income (expense)	$ (364)	$ (534)	$ (877)	$ (1,055)
Forward Contracts
Derivative [Line Items]
Contracts | derivative					4
Net gains on forward contracts			512
Designated as hedging instrument | Interest rate swap
Derivative [Line Items]
Notional amount of derivatives						$ 108,569
Designated as hedging instrument | Interest rate swap | Pay-fixed interest rate
Derivative [Line Items]
Fixed interest rate						2.05%
Designated as hedging instrument | Cross-currency swap
Derivative [Line Items]
Notional amount of derivatives						$ 108,569
Designated as hedging instrument | Cross-currency swap | Interest expense
Derivative [Line Items]
Net interest income (expense)	$ 563	$ 563	$ 1,113	$ 1,119
Designated as hedging instrument | Cross-currency swap | Pay-fixed interest rate
Derivative [Line Items]
Fixed interest rate						0.00%
Designated as hedging instrument | Cross-currency swap | Receive-fixed interest rate
Derivative [Line Items]
Fixed interest rate						2.05%

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Derivative Liability [Abstract]
Derivative assets (liabilities)	$ 7,276	$ (2,658)
Interest rate swap
Derivative Liability [Abstract]
Derivative assets (liabilities)	1,048	(2,158)
Cross-currency swap
Derivative Liability [Abstract]
Derivative assets (liabilities)	$ 6,228	$ (500)

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gains and losses from hedging instruments recognized in AOCI	$ 4,813	$ (673)	$ 7,509	$ 3,036
Interest rate swap
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedge (interest rate swap), net of tax	850	351	2,423	863
Cross-currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	$ 3,963	$ (1,024)	$ 5,086	$ 2,173

XML

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES -Summary Of Key Terms of Forward Exchange Contracts (Details) € in Thousands, kr in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Jun. 21, 2022 EUR (€)	Jun. 17, 2022 USD ($)	Jun. 17, 2022 EUR (€)
Derivative Instruments, Gain (Loss) [Line Items]
Gains and losses from hedging instruments recognized in other income or loss	$ 4,813	$ (673)	$ 7,509	$ 3,036
USD NOK Exchange | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Notional value					$ 294,555	kr 2,924,553
USD EURO Exchange | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Notional value					$ 16,640		€ 15,972	$ 6,436	€ 6,180
EURO NOK Exchange | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Notional value						kr 165,210	€ 15,972